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The role of technological advances in sodium balance and urea removal 
during hemodialysis 
Regulation of water and electrolyte balance and excretion of uremic waste products 
belong to the predominant functions of the kidney. In patients with end-stage renal 
failure, dialysis has to substitute for these functions.  
The most frequently used method for chronic dialysis treatment is hemodialysis. 
During hemodialysis, blood is separated from dialysis fluid, a highly purified solution 
with a mix of electrolytes and bicarbonate, by a semi permeable membrane (the 
dialyzer). During hemodialysis, uremic waste products and excess electrolytes, such as 
potassium, are removed by diffusion form the blood to the dialysis fluid, whereas 
water is removed by ultrafiltration (which occurs by application of a hydrostatic 
pressure gradient over the dialyzer). Hemodialysis is generally performed for a 
minimum of 3 times per week, 4-5 hours per treatment. During this treatment blood 
flows at a rate of 300 ml/min, whereas dialysis fluid flows, counter currently, at a rate 
of 500 ml/min or higher.  
This thesis focuses on these two major issues which, even after nearly 50 years of 
chronic dialysis therapy, still remain a subject of controversy in the literature, i.e. the 
regulation of sodium balance as well as the monitoring of dialysis adequacy in terms 
of urea removal.  
Especially, the role of recent technological advances in monitoring and prescribing  
1. sodium balance during hemodialysis, as well as  
2. dialysis adequacy will be the scope of investigation. 
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1 Sodium balance during hemodialysis 
Sodium and water loading in dialysis patients 
One of the main tasks of the kidney is to regulate sodium and water homeostasis, 
which it performs by a fine-tuned balance between filtration, reabsorption and 
secretion. In patients with end stage renal failure treated with hemodialysis, this 
complex role of the kidney is substituted by an artificial extracorporeal system. This is 
not an easy task given the fact that the normal kidney is working continuously (168 
hours per week). The artificial system has to equalise this task in 12-15 hours per 
week. The removal of relatively large amounts of water and sodium in such a short 
period of time may contribute to intra-dialytic hypotensive episodes, which is a 
serious limitation in the realization of “dry weight”. Moreover, adherence to a sodium 
restricted diet, which might aid in reducing inter-dialytic weight gain, is often difficult 
for dialysis patients to maintain, also given the fact that sodium is present in many 
prefabricated foods1. 
It is therefore not surprising that volume overload is very common in hemodialysis 
patients2. This chronic volume overload plays a major role in the pathogenesis of 
hypertension and subsequently left ventricular hypertrophy in dialysis patients3. 
Recently, overhydration was shown to be directly related to mortality in dialysis 
patients4. 
The main effect of a high dietary salt intake on blood pressure and volume control in 
dialysis patients may be mediated by an increase in plasma osmolality and thirst, 
leading to increased fluid intake. However, there are also arguments for an 
independent effect of sodium on blood pressure control and cardiovascular structure 
and functioning in patients with end stage renal failure. This may be related to 
disturbances in activity and or response to various neurohumoral changes, such as the 
renin-angiotensin and sympathetic nervous systems, Na-K-ATP-ase inhibitors, and the 
nitric oxide system in patients with end-stage renal failure5,6.  
The presence of an “osmotically inactive” sodium pool has recently been the focus of 
interest, although these observations have not yet been extrapolated to clinical 
practice7. Also, the relative importance of the volume independent pressor effects of 
sodium in patients with end stage renal disease is still not yet completely 
elucidated6,7. Nevertheless, it is well known that a sodium restricted diet is of great 
importance in the treatment of hypertension and may finally result in reduction of left 
ventricular hypertrophy in dialysis patients8. However, the dialysis treatment itself 
plays also a very important role in sodium balance during dialysis.  
Sodium removal during dialysis: theoretical considerations 
During dialysis, sodium transport over the dialyzer occurs both by convection as well 
as by diffusion. The relative magnitude of convection is, in general, higher as 
compared to diffusion, although data on this subject are limited in the literature.  
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Given the high importance of volume and sodium homeostasis in hemodialysis 
patients, there are surprisingly few data on sodium balance during dialysis. This might 
be partly due to the complexity of the subject. Sodium flux across the dialyzer is 
dependent on various factors, such as the rate and amount of ultrafiltration, the 
difference between the ionized sodium concentration in plasma water and dialysate, 
the concentration of sodium in dialysate and the Donnan factor (the attractive force 
for positive ions by the negative loading of plasma proteins which cannot pass the 
dialysis membrane)9.  
Sodium concentrations may be measured either in plasma or in plasma water, by 
different methods such as flame photometry, indirect ionometry and direct 
ionometry. The use of these different measure methods makes it difficult to compare 
studies. Additionally there is no consensus in what the preferred measuring method 
of sodium in plasma is, which makes the literature on this subject somewhat 
complicated.  
The amount of sodium removed by convection is related to the volume of water 
removed during ultrafiltration, i.e. more or less equal to the product of the 
ultrafiltration volume and plasma sodium concentration. Due to the Donnan effect, 
the sodium concentration in the ultrafiltrate may be somewhat lower than the sodium 
concentration in plasma water9,10,11, although large ultrafiltration volumes do not 
necessarily change the so-called "hydrosodium balance" (the relation between sodium 
and water in the body)10. 
The principle of sodium removal by diffusion is more complicated. Diffusion of sodium 
between blood and dialysate is dependent on the sodium concentration in plasma 
water and in dialysate. Under normal circumstances, sodium concentration in plasma 
water is approximately 7% (approximately 10 mmol/l) higher as compared to the 
concentration in plasma, due to the fact that the volume of plasma is higher than the 
volume of plasma water. This is caused by the fact that ±7% of plasma consists of 
plasma proteins. As proteins are not present in dialysate, a relatively large diffusion of 
sodium from patient to dialysate would be expected if sodium concentration in 
dialysate would equal plasma sodium concentration9,10. However, diffusion of sodium 
from patient to dialysate is hampered by the Donnan effect, i.e. the attraction of 
positively loaded ions by the negatively charged plasma proteins. The extent of the 
Donnan effect has been estimated around 5-10 mmol/l11. Also the binding of sodium 
with anions which might reduce the sodium “activity” available for diffusion10, may be 
somewhat higher in plasma as compared to dialysate. In plasma water, it is assumed 
that ±7 mmol/l of the total sodium concentration of ±150 mmol/l sodium is in a bound 
form versus ±4 mmol/l in dialysate9,10. 
Locatelli et al. showed that no net diffusive sodium transport between blood and 
dialysis fluid occurs when sodium concentration in plasma, as measured by flame 
photometry, is ±2 mmol/l lower than sodium concentration of dialysate. This roughly 
corresponds to a difference in sodium activity between plasma water and dialysate of 
4 mEq/l and to a Donnan effect in hemodialysis of 0.979. These findings are in 
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agreement with those of van Stone et al, who observed “isonatremic” dialysis 
treatments (i.e. no change in the hydrosodium balance) when the sodium 
concentration in the dialysate was 2% higher as compared to the plasma sodium 
concentration12,13.  
On the other hand, Flanigan showed net sodium gain when a patient with a plasma 
sodium concentration of 138 mmol/l was dialyzed against a dialysate sodium 
concentration of 140 mmol/l. The different findings between these studies might be 
due to the fact that the Donnan effect is not completely predictable due to coating of 
proteins of the dialysis membrane11,12. It can be expected that diffusive influx of 
sodium might occur with supraphysiologic dialysate sodium concentrations and in 
patients with low predialytic plasma sodium concentrations13,14. However, exact data 
on sodium balance during dialysis are surprisingly scarce in the literature. 
How can sodium balance be measured during dialysis? 
Sodium removal during dialysis therapy can be assessed by measuring sodium 
concentration in the fresh dialysis fluid and the spent dialysate (direct dialysis 
quantification) by the following formula:  
Vout x Cout – Vin x Cin, in which
  
Vout = volume of spent dialysate,  
Cout = concentration of solute
 in spent dialysate,  
Vin = volume of fresh dialysate,  
Cin = concentration
 of solute in fresh dialysate14,15.  
This impractical approach is only feasible for research purposes (collection of ± 120 
litres of dialysate per treatment in a container at the dialysis unit) and not useful for 
daily clinical practice. Sodium removal (or intake) may also be reflected by changes in 
body weight and intradialytic (or, respectively, interdialytic) changes in plasma water 
sodium concentration by the following formula17,18: 
  = predialysis total body sodium – postdialysis total body sodium 
  = predialysis plasma sodium x ((0.58 x target weight) + ultrafiltration volume) 
  – postdialysis plasma sodium x (0.58 x target weight) 
 
However, this formula assumes that total body water is 58% of body weight in dialysis 
patients, which is not necessarily correct in (all) dialysis patients19. 
Additionally, although both methods are basically physiologically sound, it is 
hampered by the variability of the different sodium measurements. It has been stated 
that an acceptable level for the variation coefficient of flame photometry and ion-
selective electrodes is 1.0 and 1.4%, respectively20,21. Although this is quite acceptable 
for clinical purposes, a difference of 2.8 mmol/l between pre- and post plasma sodium 
concentration might reflect a major change in the hydrosodium balance, but might 
also be entirely explained by a variation in the methodology. Sodium removal during 
hemodialysis can also be estimated with single-pool kinetics, for which successful 
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models have been developed22-24. Although not easily applied to daily clinical practice 
due to their complexity, these models played an important role in the development of 
measurement and feedback systems which are able to measure and model plasma 
conductivity, and assess ionic mass balance during hemodialysis (see below). 
How to measure sodium in plasma and dialysate?  
When discussing sodium concentration in plasma and dialysate, it is important to 
reflect shortly on the different methods available to measure sodium. It is important 
to distinguish between sodium concentration and sodium activity. Whereas the 
sodium concentration reflects the total amount of sodium divided by the distribution 
volume, sodium activity refers to ionic activity, which is the relevant fraction for 
diffusion2,7,10.  
Flame photometry is based on the principle that each element has its own specific 
spectrum of emission. After excitation, by an increase in temperature, electrons are 
transferred from a lower to a higher energy state. After returning to the lower energy 
state, the electrons emits a photon with a characteristic wavelength, which may 
correspond to a colour in the visible spectrum (e.g. yellow in case of sodium). Using 
flame photometry to detect plasma sodium, the change in intensity of a flame color 
after introduction of a plasma sample is assessed. Flame photometry measures total 
sodium concentration (i.e. the ionic concentration plus the amount bound with 
anions) in a plasma sample with a known volume. Normally plasma consists for 93% of 
water and for 7% of proteins and lipids. Thus, as flame photometry measures sodium 
in a sample of plasma (and not of plasma water), spuriously low plasma levels may be 
reported if the concentration of proteins or lipids in plasma increases 
(pseudohyponatremia). In dialysate, the flame photometry measures total sodium 
concentration, and due to the absence of significant proteins, pseudohyponatremia is 
not a concern.  
In contrast to flame photometry, direct ionometry measures sodium activity in plasma 
water, irrespectively of the volume in which sodium is dissolved. The sodium activity is 
converted into sodium concentration using the activity coefficient of the solution11. 
Due to the fact that 6-7% of the volume in plasma is taken by lipids and proteins (see 
above), the concentration of sodium in plasma water is 6-7% higher as compared to 
the concentration in plasma (i.e. ±149-150 mmol/l as compared to 140 mmol/l). 
Sodium activity may be lower than the actual concentration due to the bonding of 
sodium with anions such as bicarbonate. Also in dialysate, sodium activity is lower 
(±4 mmol/l) as compared to the sodium concentrations due to bonding of sodium 
with anions such as bicarbonate. Therefore, sodium concentration values reported in 
dialysate by direct ionometry may be lower as compared to the values of flame 
photometry25.  
Many laboratories use indirect ionometry to measure sodium in plasma and dialysate. 
Using indirect ionometry, a sample of plasma (not plasma water) is diluted and all 
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sodium present in the sample is ionized due to addition of a buffer, which brings the 
activity coefficient nearly to 1.0. Therefore indirect ionometry reflects the total 
sodium concentration in plasma and dialysate, and its values are comparable to those 
of flame photometry25,26. The fact that the concentration is expressed in a known 
sample of plasma (instead of in plasma water, as with direct ionometry) also means 
that with indirect ionometry, pseudohyponatremia can occur, a phenomenon that is 
not observed with direct ionometry. 
The use of different measurements of sodium concentration may thus have an effect 
on the assessment of sodium removal during dialysis, when using dialysate 
collections. In peritoneal dialysis, it has been shown that due to the bonding of 
sodium with anions in the dialysate in the course of a dwell (again: the complex is not 
measured), direct ionometry may underestimate sodium removal during dialysis as 
compared with flame photometry, whereas indirect ionometry yields results 
comparable to flame photometry25. The different methods to estimate sodium 
removal have not been compared yet during hemodialysis. However, as the 
concentration of e.g. bicarbonate in the dialysate may change during the course of the 
dialysis treatment, it is likely that the use of direct ionometry to assess sodium 
balance by direct dialysis quantification would also lead to different values as 
compared to flame photometry or indirect ionometry.  
In order to gain more insight into sodium balance during hemodialysis, frequent 
assessment of plasma sodium is mandatory. However, this is complicated by the need 
for blood sampling. Therefore, there is a need for reliable, non-invasive methodology 
by which plasma sodium and sodium balance can be assessed on a treatment-to-
treatment basis. 
Conductivity and ionic mass balance measurements in the assessment 
of sodium balance 
Conductivity of a solution is the ability to conduct an electrical current. In a watery 
solution, conductivity is related to ion content. It has been shown that a linear relation 
exists between the sodium content and conductivity of dialysate and plasma 
(water)27,28,29. Therefore, it has been postulated that conductivity can substitute for 
sodium concentration in plasma and dialysate27. Plasma conductivity (PC) can be 
assessed non invasively by measurement of ionic dialysance (D). In turn, ionic 
dialysance is assessed by measurement of dialysate conductivity at the dialyzer inlet 
(Cdin) and outlet (Cdout) after changing the dialysate inlet concentration (i.e. the 
smaller the change in conductivity at the dialysate outlet after changing the dialysate 
















Figure 1.1 Scheme of the record of the inlet and outlet dialysate conductivity during a measurement of 
ionic dialysance where X1 and X2 are the two given values of inlet dialysate conductivity, Y1 
and Y2 the two measured values of outlet dialysate conductivity and Cp the representation of 
the patient's plasma conductivity. QD is dialysateflow, QF ultrafiltration rate. 
 
 
The conductivity model does not need to take the Donnan effect into account, 
because conductivity is determined by both positive and negative ions in the 
solution25. As will be discussed later, the conductivity kinetic model can substitute for 
the sodium kinetic model in predicting post-dialytic plasma conductivity (as a 
substitute for sodium). 
With the Diascan module in the Hospal Integra device, plasma conductivity (PC) is 
calculated by measuring ionic dialysance (D) in combination with dialysate flow (Qd) 
and dialysate conductivity measurements at the dialyzer inlet (Cdin) and outlet (Cdout), 
according to the formula: 
PC = [Cdout – (1 – D/Qdin) x Cdin] / (D/Qdin).
  
D is assessed every 30 min during dialysis treatment by measuring the increase in 
Cdout
 after a temporary increase in Cdin by 1 mS/cm according to the
 formula: 
D = (Qdin + Qf) x [1 – (Cdout1 – Cdout2) / (Cdin1 –
 Cdin2)]
27,28,30.  
1 and 2 indicate, respectively measurements before and after the temporary increase 
in Cdin respectively, Qdin is dialysate flow at inlet and Qf is ultrafiltration rate. 
Empirically, plasma sodium was shown to be approximately 4 mmol/l lower than PC 
multiplied by 1027, whereas sodium concentration in plasma water is slightly higher 
than PC x 1028. As will be discussed later, ionic dialysance is strongly related to urea 
clearance, and therefore this method has also been introduced for assessment of 
dialysis adequacy. 
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In addition, sodium balance can be approximated by assessing ionic mass balance 
(IMB) by constant measurement of the conductivity in the dialysis outlet and inlet 
according to the formula: 
IMB = [(Qdout x Cdout) - (Qdin x Cdin)]
 x 10 x time (min)  
Qdout= dialysate flow at
 outlet 
Cdout = dialysate conductivity
 at outlet 
Qdin  = dialysate flow at inlet 
Cdin  = dialysate conductivity
 at outlet 
 
Although the sodium concentration is by far the greatest determinant of dialysate 
conductivity29 the transfer of other ions such as potassium or bicarbonate might also 
influence ionic mass removal during dialysis. 
The relation between sodium removal (estimated from pre- and postdialytic plasma 
sodium measurements, using the formula described above) and ionic mass balance 
was assessed by Lambie et al. The r2 between both methods was 0.66 whereas IMB 
underestimated sodium loss by 14.8 ± 3.3% compared to the reference method. Still, 
also the inherent variation in plasma sodium measurements (see above) should be 
taken into account when assessing sodium balance by means of pre- and post-dialytic 
plasma sodium concentrations. Until now, IMB has not yet been validated using direct 
dialysis quantification.  
The use of dialysate sodium in clinical practice  
During dialysis, water and sodium are removed by controlled ultrafiltration resulting 
from the application of a hydrostatic gradient over the dialyzer. In contrast, due to 
their structure (the small surface area and the lack of permeability of the membrane), 
early dialysis systems were incapable of controlled ultrafiltration31. Water and sodium 
were removed by osmotic ultrafiltration, by using a high concentration of glucose in 
the dialysate (comparable to the ultrafiltration mechanism of peritoneal dialysis), in 
combination with a low sodium concentration of the dialysate (126 mmol/l). Dialysis 
treatment time in the earlier days of dialysis was much longer compared to the 
current policy of time (often > 8 hours/treatment versus 3 to 4 hours/treatment). The 
improved design of the dialyzer, blood pumps, and negative pressure dialysis 
modules, made removal of sodium and water by controlled ultrafiltration possible. 
Solute clearance was increased by using larger dialyzer surface areas, which permitted 
shortened dialysis times. The high clearance of uremic solutes resulted in rapid 
changes in plasma osmolality. This provoked the so-called dialysis disequilibrium 
syndrome, characterized by fatigue, nausea, muscle cramps and, in severe cases, brain 
oedema due to water transport from extracellular to intracellular compartment. In 
order to prevent the disequilibrium syndrome, and because low sodium dialysate was 
no longer necessary for sodium and water removal, dialysate sodium concentration 
was increased gradually to 130-135 mmol/l in the early eighties10, which reduced the 
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osmotic shift of water from the extracellular to the intracellular compartments. 
However, due to the decrease in dialysis time to approximately 4 hours, water and 
sodium had to be removed in a shorter time period, resulting in an increased risk of 
episodes of intra-dialytic hypotension.  
A decline in blood volume during hemodialysis plays an important role in the 
pathogenesis of intra-dialytic hypotension. The decline in blood volume during dialysis 
is a resultant of the ultrafiltrated volume and refill from the interstitial compartments. 
With increased dialysate sodium concentrations, fluid shifts from the intracellular 
compartments to the extracellular and intravascular compartments is increased. This 
has led to the prescription of higher dialysate sodium concentrations. In a recent 
survey of Davenport et al. in 439 chronic dialysis patients, 251 were treated with a 
dialysate sodium concentration of 140 mmol/l, 132 with a concentration of 
137-139 mmol/l, and 52 with a concentration of 136 mmol/l32. In the Netherlands* 

















*In general, dialysate conductivity of 14.0 mS/cm corresponds approximately to dialysate sodium 
concentration of 140 mmol/l with standard dialysate bicarbonate concentration of 34 mmol/l. In case of 
higher or lower dialysate bicarbonate concentration the conductivity will slightly differ 
Dialysate sodium as a tool to prevent intra-dialytic hypotension  
Despite changes in dialysis prescription, such as the use of lower dialysate 
temperatures, the appearance of intra-dialytic hypotensive episodes in dialysis 
patients is still regularly. Intra-dialytic hypotension not only results in patient 
discomfort but also may increase the risk of myocardial and cerebral ischemia33. 
Probably due to an improved refill of plasma volume by increasing tonicity of the 
extracellular compartment, the use of high dialysate sodium concentrations 
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not in all studies36. A beneficial effect on hemodynamic stability during dialysis was 
also observed for sodium profiles, in which dialysate sodium is modelled (most often 
from values up to 150 mmol/l at the start of dialysis to 140 mmol/l at the end of 
dialysis)34,37. Various studies found a reduction in intra-dialytic hypotension with the 
use of sodium profiles34,37,38 which are also mentioned as a therapeutic option by 
K-DOQI guidelines39.  
However, sodium profiles may not be effective in all patients with frequent intra-
dialytic hypotension40. Unfortunately the use of both, high sodium dialysate and 
sodium profiles may lead to increased thirst, inter-dialytic weight gain, and 
hypertension36,38,40,41. Few studies have addressed this long term effect of sodium 
profiles on sodium balance and plasma sodium concentration in dialysis patients. 
Therefore, the use of sodium profiles in the prevention of intra-dialytic hypotension is 
still a matter of controversy33.  
Individualization of dialysate sodium, variation in plasma sodium 
concentration 
In order to prevent possible patient discomfort due to either diffusive sodium loading 
from dialysate to patient (cellular overhydration) or excessive diffusive sodium loss 
(intradialytic hypotension), individualization of the dialysate sodium might be a 
solution. This so-called zero hydrosodium balance causes removal of the exact 
quantity of sodium that has accumulated in the inter-dialysis period to reach a zero 
balance42. Prescribing dialysate sodium as the plasma sodium concentration was 
found to improve both hemodynamic stability during dialysis as well as inter-dialytic 
blood pressure control43. For the prescription of individualized sodium dialysis, the 
pre-dialytic plasma concentration has to be known40. Therefore the use of 
individualized sodium prescription would be facilitated if pre-dialytic plasma sodium 
was found to be a stable entity.  
Indeed, a fixed sodium set point is assumed by various authors11,44,45. Although pre-
dialytic plasma sodium appeared to be relatively stable in a small study of Flanigan et 
al., the coefficient of variation in a cohort of non-diabetic dialysis patients during 12 
consecutive months was 2%. Whereas this appears small, it corresponds to a range of 
137-143 mmol/l in a patient with a mean pre-dialytic plasma sodium concentration of 
140 mmol/l, which may have a major effect on diffusive sodium balance during 
dialysis, as discussed previously. At this moment, few studies assessed the variability 
of pre-dialytic plasma sodium concentrations in dialysis patients. Also, the relation 
between variations in plasma sodium and clinical parameters, such as inter-dialytic 
weight gain and blood pressure, has not been assessed. 
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On-line feedback models to control plasma conductivity and blood 
volume  
In 1980, Gotch23 developed a single-pool sodium kinetic model for hemodialysis (HD) 
in order to obtain a zero sodium balance over the treatment cycle (intra-HD sodium 
removal = inter-HD sodium accumulation). Using flame photometry to determine total 
sodium concentrations, this early analytical single-pool kinetic model showed a degree 
of imprecision of ~2.8 mmol/l in predicting end-dialysis plasma water sodium 
concentration. This means, for a final total body water volume of 40 litres (58% for 
70 kg body weight), an imprecision of ~112 mmol in predicting sodium removal with 
dialysis. However, on the basis of Gotch's theoretical premises, Di Filippo46 
demonstrated more recently, using direct ionometry, a level of imprecision in the 
prediction of sodium balance of less then 34 mmol. Unfortunately, these models are 
unsuitable for routine clinical use because of the need for blood sampling and 
laboratory determinations at each dialysis session.  
Recently, it has become possible to model the decline in blood volume and changes in 
plasma conductivity (PC), as a surrogate of plasma sodium, by means of feedback 
technologies. Following the theoretical premises of conductivity monitoring; i.e. 
dialysate and plasma sodium are linearly related to conductivity, a conductivity kinetic 
model can be used instead of a sodium kinetic model, which can be achieved by a 
dialysis module which is able to measure dialysis conductivity and ionic dialysance on-
line, by which plasma conductivity can be assessed and modelled47,48. 
In the case of PC-controlled feedback, a target for end-dialytic PC is set, which is 
achieved by frequent adjustments of dialysate conductivity during the dialysis 
sessions, in response to on-line measured changes in PC29,49,50. With PC-controlled 
feedback (Diacontrol®; Hospal-Gambro, Mirandola, Italy), PC is modelled 
automatically during dialysis by adjustment of DC using single-pool kinetic modelling. 
With PC-controlled feedback, it is possible to achieve these targets with a high level of 
precision. Post-dialytic plasma conductivity can be assessed with a precision of 
<0.14 mS/cm (~1.4 mmol/l)47. Unfortunately, clinical experience with conductivity-
controlled feedback in particular is still limited50,51. In one study in patients treated 
with paired filtration dialysis (a modification of haemodiafiltration in which convection 
and diffusion take place separately) conductivity controlled feedback resulted in a 
decline in incidence in intra-HD hypotension51. Comparable results were reported in 
patients treated with hemodialysis, although these studies have only been published 
in abstract form52,53. These results are nevertheless promising, but the effect of 
conductivity controlled feedback has not been compared yet with other strategies in 
the prevention of intra-dialytic hypotension. Moreover, the use of a preset post-
dialytic plasma conductivity target in the “physiologic range”54 (i.e. 14.0-14.2 mS/cm, 
roughly corresponding to a plasma sodium concentration of 138-140 mmol/l) might 
possibly lead to reduced sodium loading in patients with low pre-dialytic plasma 
sodium levels28,29,49. The effect of conductivity controlled feedback, which is only 
22⏐Chapter 1 
available on a single dialysis module (Diacontrol®), on sodium balance in comparison 
with other treatment strategies has also not been studied.  
Another, more used, feedback method in the prevention of hemodynamic instability is 
blood-volume controlled feedback systems. Blood volume controlled feedback 
prevents a decline in blood volume below an individually set threshold by continuous 
adjustments of the ultrafiltration rate and dialysate conductivity in response to 
measured changes in relative blood volume. This threshold is based on an empirically 
determined relative blood volume below which the patient is known to develop 
complaints. Relative blood volume can be assessed during dialysis by measuring the 
change in hematocrit or protein content by optical methods or ultrasound55.  
The biofeedback system used in this thesis (Hemocontrol®; Hospal-Gambro, 
Mirandola, Italy) is based on a closed-loop automatic control system using three 
controlled variables and two control variables. These controlled variables are total 
weight loss, change in relative blood volume, and equivalent conductivity. Equivalent 
conductivity is a value which is defined as the mean dialysate conductivity value 
required to achieve the same sodium mass balance compared to standard 
hemodialysis with a fixed conductivity. The control variables consist of the 
ultrafiltration rate and the delivered dialysate conductivity. Discrepancies between 
ideal and achieved controlled variable values are processed by a multi-input/multi-
output controller that in turn effectuates a response through the two actuators, the 
control variables ultrafiltration rate and dialysate conductivity. Changes in blood 
volume are determined by continuous relative blood volume monitoring. Total weight 
loss is measured volumetrically.  
Although the mean dialysate conductivity is usually set at a “physiologic” level 
(14.0-14.2 mS/cm (~140-142 mmol/l), the effect of these rapid fluctuations of 
dialysate conductivity on ionic removal has not yet been studied. Most studies, 
however, have not reported important changes in plasma sodium levels during 
biofeedback treatment. Blood volume controlled feedback, though shown to be 
effective in reducing intra-dialytic hypotension, has not been compared with other 
methods in the prevention of intra-dialytic hypotension. Also, the effect of blood 
volume controlled feedback on sodium balance has not been assessed in detail56-59.  
The discussion above shows that many issues regarding sodium balance in 
hemodialysis therapy still remain unanswered.  
 Introduction⏐23 
2 Dialysis adequacy  
Dialysis adequacy estimated by urea removal 
The second part of the thesis focuses on the monitoring of dialysis adequacy.  
Next to restoration of the water, electrolyte, and acid-base balance of the body, the 
removal of uremic toxins is the main goal of dialysis therapy. Although many uremic 
toxins are responsible for the uremic syndrome60,61 (only the removal of urea is used 
as a marker of dialysis adequacy, although urea per se does not appear to be highly 
toxic. However, urea removal indices were found to be related to outcome (ref. NCDS) 
and plasma urea is easy to measure, whereas the kinetic modelling of urea during 
dialysis is relatively straightforward62. Other relevant uremic toxins, such as phosphate 
or β-2 microglobulin, have different kinetics compared to urea63.  
Urea reduction ratio (URR) 
The most simple method to express dialysis adequacy in terms of urea removal is the 
urea reduction ratio (URR), for which only pre- and post-dialytic plasma urea 
concentration is needed. It can be expressed as: 
(1 - Cend/C0) x 100  
Cend = urea concentration at the end of dialysis 
C0 = urea concentration at the start of dialysis.  
URR is easy to calculate and is therefore widely used in clinical practice64. However, a 
serious drawback of the use of URR resides in the fact that urea removal by 
ultrafiltration is not taken into account, nor the urea generation during dialysis. Thus, 
its application in individual therapy quantification introduces significant errors. It has 
been suggested that due to these limitations, the use of URR as index of dialysis dose 
might have a negative effect on treatment outcome and should not be used, although 
some studies showed a good correlation between URR and survival65,66,67 
Neither European Best Practice Guidelines (EBPG) nor Kidney Disease Outcomes 
Quality Initiative (K-DOQI) advocate URR as an appropriate method for assessing 
dialysis adequacy68,69,70. In the 2007 EBPG on dialysis strategies it has been suggested 
that URR should be used as an approximation for practical purposes, but not as a 
substitute for formal urea kinetic modelling69. 
Single pool Kt/Vurea (spKt/V) 
spKt/V is the most commonly used marker to express dialysis dose, and its use is 
advocated by both K-DOQI and EBPG guidelines. Kt stands for dialyzer clearance (K) x 
dialysis time (t), which can be considered as the amount of blood which is cleared of 
urea during a dialysis treatment. V stands for the amount of urea distribution volume 
of the patient. Therefore, spKt/V is a dimensionless unit. With a spKt/V of 1.0, 
basically a volume of blood equal to the urea distribution volume has been totally 
24⏐Chapter 1 
cleared of urea. With spKt/V, urea generation during dialysis, as well as urea removal 
during ultrafiltration is taken into account. 
 
The following formula for spKt/V is advocated in K-DOQI guidelines70: 
 
spKt/V=  
C0, Cend = urea concentration at start and end-session 
Uf =   ultrafiltration volume  
Wt =  post-dialytic body weight (kg) 
t =  treatment time in hours 
 
With this formula, urea removal during dialysis is calculated according to single-pool 
kinetics. However, after dialysis, significant rebound of urea is observed, showing that 
urea kinetics do not follow a single pool model.  
Which types of rebound can be distinguished?  
There are three main causes of rebound after dialysis. The first type of rebound, 
occurring within 15–20 seconds after the end of dialysis is a result of access 
recirculation, if present. The effect of access recirculation can be circumvented by the 
methodology of post-dialytic blood sampling. The most used method is the “slow-
flow” method, by which the speed of the dialyzer blood pump is reduced 15 seconds 
before the termination of dialysis. Immediate stopping of the blood pump may lead to 
‘freezing’ of the blood sample and therefore to underestimation of the actual plasma 
urea concentration when access recirculation is present70. 
The second type of rebound is a result of cardiopulmonary recirculation, which takes 
place until 1–2 minutes after the end of dialysis. Cardiopulmonary recirculation occurs 
because a part of the purified blood, which returns to the heart, flows immediately 
back to the fistula without passing the tissues. Cardiopulmonary recirculation is 
inherently present in every haemodialysis treatment, except in patients with central 
venous catheters71. However, the effect of cardiopulmonary recirculation on urea 
rebound does not appear to be very large72. The effect of cardiopulmonary 
recirculation can be circumvented by taking the blood sample 3 minutes after the end 
of dialysis70. 
The third type of rebound, which appears to be a result of a disequilibrium of urea 
distribution within different body pools, and is lasting until 30–60 minutes after the 
end of dialysis, depending on the intensity of dialysis. It has been shown that 99% of 
the post-dialytic urea rebound was complete at 48 minutes and 94% at 30 minutes73 
after haemodialysis treatment. The cause of this phenomenon is still subject of debate 
and different hypotheses. A first hypothesis assumes that during dialysis, a 
















because of resistance of the cell membrane to urea transport, which leads to rebound 
of urea from the intracellular space after the end of dialysis. A second hypothesis 
(regional flow model) assumes that this phenomenon is caused by the differences in 
perfusion of various tissues, which may lead to rebound of urea from the less well 
perfused regions of the body70,74,75.  
Equilibrated double pool Kt/Vurea
 (eKt/V) 
The best way to compensate for rebound due to urea redistribution is to measure 
blood urea 30–60 minutes after the end of dialysis. Despite the fact that rebound may 
not be entirely complete, the eKt/V, which takes the 30-minutes post-dialytic sample 
into account, is often used in the literature as the reference method76. However, this 
approach is cumbersome in clinical practice, both for hospital staff and patients. 
Therefore, several formulae have been developed in order to compensate for urea 
disequilibrium. One of the most frequently used formulae is the empirically derived 
Daugirdas–Schneditz formula, which corrects the single-pool Kt/V for treatment 
time77. The derived values were found to be well related to the actual equilibrated 
Kt/V, and seem to be as reliable as values based on dialysate collection techniques76.  
 
The most commonly used formula for eKt/V, based on the regional blood flow two-
pool urea kinetic model is: 
eKt/V=  ( ) 0.03
t
spKt/V0.6spKt/V +×−  
t =  treatment time in hours 
spKt/V =  singlepool Kt/Vurea 
 
In general, also depending on the duration of dialysis, eKt/V is 0.15-0.20 lower than 
spKt/V.  
In contrast to K-DOQI, the eKt/V is advocated by the EBPG guidelines as the preferred 
tool to assess dialysis adequacy. Reasons for K-DOQI not to prescribe eKt/V as 
benchmark for dialysis adequacy are its mathematical relation to spKt/V, and the fact 
that shortened dialysis time (which increase the discrepancy between spKt/V and 
eKt/V) are disallowed by K-DOQI guidelines. In general, K-DOQI did not consider the 
evidence for the use of eKt/V instead of spKt/V of sufficient strength to justify the 
additional effort and target range70. 
As reaching the target levels of Kt/Vurea is associated with improved survival and 
decreased incidence and duration of hospitalization78,79, the discussion whether URR, 
eKt/V or spKt/V should be the preferred parameter in the assessment of dialysis 
adequacy remains. 
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Dialysis adequacy estimated from ionic dialysance  
Current guidelines advocate to assess Kt/Vurea at least at a monthly basis. However, 
considerable variation in delivered dialysis dose has been observed between 
individual dialysis sessions80. This would, given the relation between Kt/Vurea and 
clinical outcomes78,79 justify more frequent assessment of dialysis dose. However, for 
assessment of Kt/V by formal urea kinetic modelling pre- and post-dialysis blood 
sampling is needed, which makes more frequent assessment of Kt/Vurea  by the 
standard approach, impractical. Therefore, reliable non-invasive assessment of dialysis 
dose would be a great asset for clinical practice.  
An increasingly used method is the estimation of Kt/Vurea from ionic
 dialysance (Kt/Vid). 
As discussed in the previous section, ionic dialysance can be assessed during the 
dialysis session by temporarily increasing dialysate conductivity (~ equivalent to the 
dialysate sodium concentration) in the inlet port of the dialyzer and measuring the 
change in conductivity at the dialysate outlet81,86. The effective ionic dialysance and 
the plasma conductivity of the patient are measured in an automated and non-
invasive way. The underlying assumption is that plasma conductivity does not change 
during temporary changes in dialysate conductivity because of the large sodium 
distribution pool82, although this assumption has been questioned83. Urea clearance 
can be assessed from ionic dialysance because sodium and urea have comparable 
molecular weights. This technique has already been integrated on some commercially 
available dialysis modules. Its great advantage would be the presence of an 
inexpensive, readily available on-line estimation of dialysis adequacy and sodium 
removal, which can be assessed at every dialysis treatment. In several studies, Kt/Vid 
appeared to be well related to Kt/Vurea
84, although in some studies85, an 
underestimation of Kt/Vid was observed as compared to Kt/Vurea. This was explained 
by the effects of cardiopulmonary recirculation, which would tend to overestimate 
“true” urea removal86,87,88. Indeed, Mercadal et al. observed that after correction for 
recirculation, urea clearance and ionic dialysance were equivalent88. Other authors83 
though attributed differences between ionic dialysance and urea removal to changes 
in the total body sodium pool due to the effect of conductivity pulses themselves. In 
addition, also the dialyser clearance and the charge of the dialysis membrane may 
influence the relation between ionic dialysance and urea clearance. 
The influence of the estimation of urea distribution volume on Kt/Vid 
Also the estimate of urea distribution volume deserves attention in the assessment of 
Kt/Vid. The ionic
 dialysance method only takes clearance and treatment time into 
account (Kt), whereas the V component has to be derived from anthropometric 
formulae or kinetic modelling. Nevertheless, several studies questioned the reliability 
of these anthropometry-based equations89,90. In general, anthropometry-derived 
equations appear to underestimate the true urea distribution volume, which would 
partly offset the effect of underestimation urea clearance by ionic dialysance86. 
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Assessment of V by urea kinetic modelling (Vukm) may be more
 reliable than 
anthropometric derived V91. Recently, an estimate of V which was calculated with the 
use of ionic dialysance measurements (VIOD) themselves has been proposed (VIOD),
 
which correlated very well with V obtained by direct dialysis quantification and bio-
impedance measurements92,93. A comparison of VIOD with other estimates of V 
regarding the agreement between Kt/V, assessed by eKt/V and Kt/Vid was only 




Appendix Mathematical definitions  
 
1. Sodium balance: Vout x Cout – Vin x Cin 
 
2.   Sodium balance: 
  = predialysis total body sodium–postdialysis total body sodium 
  = predialysis plasma sodium x ((0.58 x target weight)+ultrafiltration volume) 
  - postdialysis plasma sodium x (0.58 x target weight) 
 
3. PC = [Cdout – (1 – D/ Qdin) x Cdin] / (D/ Qdin) 
 
4. D = (Qdin + Qf) x [1 – (Cdout1 – Cdout2) / (Cdin1 – Cdin2)] 
 
5. IMB = [(Qdout x Cdout) - (Qdin x Cdin)] x 10 x time (min)  
 
6. URR = (1 - Cend/C0) x 100 
 







9. V (Watson):  
males:   WtHtA ⋅+⋅+⋅− 3362,01074,009516,0447,2  
 females:  WtHt ⋅+⋅+− 2466,01069,0097,2  
 
 
Vout = volume of spent dialysate,  
Cout = concentration of solute
 in spent dialysate 
Vin = volume of fresh dialysate,  
Cin = concentration
 of solute in fresh dialysate 
PC =  plasma conductivity 
Qf = ultrafiltration rate 
D =  ionic dialysance 
Qdout= dialysate flow at
 outlet 
Cdout = dialysate conductivity
 at outlet 
Qdin  = dialysate flow at inlet 
Cdin  = dialysate conductivity
 at inlet 



















Cend = urea concentration at end-session 
Uf = ultrafiltration volume (in liters) 
Wt = post-dialytic body weight (in kilograms) 
Ht = length (in centimetres) 
A = age (in years) 
t  = treatment time (in hours) 
spKt/V = singlepool Kt/V 
eKt/V  = equilibrated, double pool Kt/V 
URR = Urea Reduction Rate 
Vwatson  = urea distribution volume calculated by the Watson  formula 
VIOD =  urea distribution volume calculated by the ionic dialysance formula 
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Aim and outline of the thesis 
The objective of this thesis is to study the added value in clinical practice of 
technological advances during hemodialysis by examining the influence of the 
following issues. 
Variations in pre-dialytic plasma conductivity and the effect on ionic 
mass balance 
In Chapter 3 we describe how differences in dialysis sodium prescription affect 
diffusive ionic mass balance during a single dialysis session. Moreover , ionic mass 
balance by on-line conductivity measurements is validated against conductivity 
measurements in spent dialysate collections. In Chapter 4 the long term variation in 
pre-dialytic plasma conductivity in hemodialysis patients treated with a fixed dialysate 
sodium concentration is addressed. In addition, the relation between variations in 
plasma conductivity and clinical parameters, such as inter-dialytic weight gain and 
blood pressure is studied. Furthermore, it is studied to which extent differences in 
pre-dialytic plasma conductivity result in differences in (diffusive) ionic mass balance. 
In this chapter, ionic mass balance is validated using sodium balance measurements 
by direct dialysate quantification. In Chapter 5 the influence of sodium profiling as 
well as blood volume controlled feedback and conductivity controlled feedback on 
ionic mass balance is addressed. Additionally,the effects on hemodynamic stability of 
these different treatment modalities is studied. The effect of the imposed rapid 
fluctuations of dialysate conductivity during the assessment of plasma conductivity 
and ionic dialysance has not yet been studied. In Chapter 6 the effect of ionic 
dialysance measurements on sodium load is assessed. 
The different parameters for estimating dialysis adequacy and the 
effect on outcome 
Chapter 7 studies the effects of treatment monitoring with different parameters of 
dialysis adequacy based on urea kinetic modelling, i.e. the urea reduction rate, eKt/V 
and spKt/V. This study was carried out in the NECOSAD cohort and addresses which 
percentage of patients would be classified as receiving an “adequate” or “inadequate” 
treatment dose based on target and minimally adequate levels of these different 
parameters. In addition also the prognostic significance of the different adequacy 
parameters will be discussed. In Chapter 8 the agreement between Kt/V assessed by 
ionic dialysance and by formal urea kinetic modelling is assessed. Furthermore the 
effect of different estimates of urea distribution volume on dialysis adequacy on 
dialysis adequacy estimation is discussed. The mechanisms between the inter-
treatment variability of Kt/V by ionic dialysance are also studied.  
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In Chapter 9, the results of the studies in the thesis are summarized and their 
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Although a higher dialysate sodium concentration (DNa) is frequently used to improve hemodynamic 
stability during haemodialysis, few studies have compared ionic mass balance (IMB) during different DNa. 
Moreover, DNa is usually a standard prescription, whereas inter-individual pre-dialytic serum sodium levels 
may differ widely. The aims of the study were to assess IMB and the decline in blood volume (ΔBV) during 
isovolaemic HD as well as during HD combined with ultrafiltration (UF) during DNa [140], DNa [144], and an 
individualized DNa [ind], in which DNa is equal to pre-HD plasma conductivity x 10.  
 
Methods 
IMB and plasma conductivity were assessed by on-line conductivity measurements (Diascan®; Hospal®) in 
13 HD patients. After one hour of isovolaemic HD, measurements were continued during UF+HD until dry 
weight. ΔBV was assessed by an optical method (Hemoscan®).  
 
Results 
During isovolaemic HD with DNa [140] and [144], Pre-Na was significantly related to IMB (r=0.83 and r=0.61; 
P<0.05). Diffusive ionic mass influx from dialysate to patient occurred when the difference between DNa 
and pre-dialytic plasma sodium was larger than 5 mmol/l. During UF+HD, IMB was 318±166 mmol during 
DNa [140], 277±116 mmol during DNa [ind], and 239±111 during DNa [144] (mean±SD; P<0.05 compared 
with the other treatment modalities) whereas ΔBV did not differ significantly. In the five patients with a pre-
dialytic sodium concentration below 140 mmol/l, ionic removal was significantly higher during DNa [ind] 
(324±87) compared with DNa [140] (228±127 mmol; P<0.05) without a significant difference in BV (-9.7±1.6 
vs  -7.8±2.3%). 
 
Conclusion 
A large difference in IMB was observed between DNa 144 and DNa 140, without a significant difference in 
ΔBV. In patients with low pre-dialytic serum sodium levels, diffusive ionic influx from the dialysate into the 
patient may occur. In patients with low pre-dialytic sodium levels, DNa [ind] leads to an enhanced ionic 
removal compared with DNa [140] without large differences in ΔBV. 
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Introduction 
The dialysate  sodium  concentration  is a  two‐edged  sword. Whereas a  low dialysate 
sodium concentration may  lead  to  large  removal of  sodium but also  to an  impaired 
preservation  of  blood  volume  provoking  intra‐dialytic  hypotension,  a  high  dialysate 
sodium  concentration may  improve hemodynamic  stability during dialysis,  although 
possibly  at  the  cost  of  increased  inter‐dialytic  weight  gain  and  hypertension.  In 
general,  an  optimal  dialysate  sodium  concentration would  find  a  balance  between 
both an adequate blood volume preservation and sodium removal1. In earlier studies, 
but  also  more  recently2,3,  several  authors  recommended  higher  dialysate  sodium 
concentrations  in  order  to  prevent  intra‐dialytic  hemodynamic  instability  in 
hypotension‐prone dialysis patients2,3. Few data are, however, available on ionic mass 
balance (IMB) during dialysis with different dialysate sodium concentrations, although 
such  data  are  of  pivotal  importance  in  view  of  the  relation  between  sodium, 
hypertension, and left ventricular abnormalities in dialysis patients4–6. 
In most of  the  literature,  the dialysate  sodium  concentration  is  seen  as  a  standard 
prescription,  whereas  the  pre‐dialytic  plasma  sodium  concentration  may  differ 
between  dialysis  patients.  The  fact  that  this  phenomenon may  lead  to  large  inter‐











by ultrafiltration and purely diffusive  ionic  transport. The aims of  the present  study 
were  to  first  assess  IMB  in  vivo  both  during  isovolaemic  dialysis  as well  as  during 
haemodialysis  combined  with  ultrafiltration  using  different  dialysate  sodium 
concentrations,  and  secondly  to  compare  standard  and  individualized  dialysate 
sodium concentrations in terms of blood volume preservation and IMB. 
42⏐Chapter 3 
Subjects and methods 
Study protocol 
Validation study 
During nine treatment sessions, IMB was assessed both by Diascan® (vide infra) and by 
direct dialysis quantification. Using direct dialysis quantification, the total amount of 
spent dialysate was collected in a box. Conductivity measurements were performed in 
a sample of spent dialysate taken from the box, as well as in a sample of incoming 
dialysate. IMB by direct dialysis quantification was assessed according to the formula: 
 (CdinxQd x dialysis time)-(Vdout x Cdout),
 in which 
Qd is dialysate flow,  
Cdin is dialysate conductivity
 of incoming dialysate,  
Vdout is volume of spent dialysate, and
  
Cdout is the conductivity of spent dialysate. Conductivity of
 incoming and spent 
dialysate was measured with a conductivity meter (IBP HDN-90, Hannover, Germany). 
Moreover, sodium concentration of incoming dialysate was assessed by ionometry 
(Vitros 950®; Johnson and Johnson).  
Clinical study 
Patients were studied during three dialysis sessions with dialysate sodium 
concentrations of, respectively, 140 mmol/l (14mS/cm) {DNa [140]}, and 144 mmol/l 
(14.4mS/cm) {DNa [144]}, and an individualized sodium concentration {DNa [ind]}. 
Dialysate sodium was individualized according to pre-dialytic plasma conductivity 
(dialysate sodium is equal to pre-dialytic plasma conductivityx10), as measured by 
Diascan® (Hospal®) (vide infra). Three different dialysis sessions with, respectively, 
DNa [140], DNa [144], and DNa [ind] were compared, in randomized order. Sessions 
were performed at exact intervals of one week, in order to prevent large differences 
in ultrafiltration volume and also to prevent an effect of a previous modification of 
dialysate sodium on the subsequent study sessions. In the other dialysis treatments, 
during which no measurements were performed, a dialysate sodium concentration of 
140 mmol/l was used, as was standard policy in our clinic at the time of the 
investigation. 
During each session, patients were first studied during one hour of isovolaemic 
dialysis, followed by combined ultrafiltration and haemodialysis until clinical dry 
weight, using the same dialysate sodium concentration. Parameters assessed were 
IMB, relative blood volume, serum sodium, and plasma conductivity, which were 
measured at the start of the study, after one hour of isovolaemic dialysis, and at the 
end of the dialysis session (after combined haemodialysis and ultrafiltration).  
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Patients 
Thirteen patients were included in the study (eight male; five female). Mean±SD age 
of the patients was 65.5±16.0 years (range 26–81). Patients with acute renal 
insufficiency with severe hypotensive episodes were excluded. Mean dry body weight 
was 66.8±12.2 kg (range 43–92). Seven patients still had residual renal function. Mean 
urine volume in the patient group was 770±91 ml/day (range 0–2.25 l). All patients 
gave informed consent for participation in the study.  
Dialysis schedule 
The dialysis schedule of the patients was twice weekly in five patients and three times 
a week in eight patients. Mean treatment time was 231±23 min (range 180–270). 
Polysulfone (F8HPS; Fresenius®) dialysis membranes were used. Composition of the 
dialysate was: potassium 2.0 mmol/l, calcium 1.5 mmol/l, magnesium 0.5 mmol/l, 
bicarbonate 32 mmol/l, acetate 3.0 mmol/l, and glucose 1 g/l. Temperature of the 
dialysate was 36°C. Patients were ultrafiltered until their clinically determined dry 
weight.  
Study parameters 
Ionic mass balance 
IMB was estimated by Diascan® (Hospal®)7,8. In short, Diascan® measures IMB by 
constant measurement of the conductivity in the dialysis outlet and inlet according to 
the formula: 
 IMB = [(Qdout x Cdout) - (Qdin x Cdin)] x 10 x time
 (min).  
Qdout and Qdin are dialysate flow at, respectively, outlet
 and inlet; Cdout and Cdin are 
dialysate conductivity at, respectively, outlet and inlet. A positive IMB means sodium 
removal from the patient, a negative IMB means sodium transport to the patient. 
Plasma conductivity 
Plasma conductivity (Pc) is measured by Diascan® by measuring
 dialysance (D) in 
combination with measurements of Cdout and
 Cdin according to the formula: 
Pc = [Cdout – (1 – D/Qdin) x Cdin]/(D/Qdin).
  
D is assessed every 30 min by measuring the increase in Cdout
 after a temporary 
increase in Cdin by 1 ms/cm according to the
 formula: 
D = (Qdin + Qf) x [1 – (Cdout1 – Cdout2)/(Cdin1 –
 Cdin2)],  
where 1 and 2 indicate, the measurements before and after the temporary increase in 
Cdin
7,8 respectively, Qdin is dialysate flow at inlet and Qf is ultrafiltration rate. 
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Relative blood volume 
Blood volume was measured continuously by continuous optical assessment of 
changes in hemoglobin during the dialysis session (Hemoscan®)9.  
Serum sodium 
Serum sodium was assessed by ionometry (Vitros 950®), which assesses sodium 
activity in the serum. Sodium activity is automatically converted to the molar ionized 
sodium concentration. Obtained values were corrected by converting the molar 
concentration to flame photometer values by a standard correction factor (0.93)10. 
The coefficient of variation for this method, as given by the manufacturer, is 0.4%.  
Statistical analysis 
Results obtained at the different treatment sessions were compared using Friedman's 
ANOVA and, if significant, further analysed by a Wilcoxon test. Correlations between 
variables were assessed by Pearson's r. P values <0.05 were considered significant. 
Statistical analysis was performed using a SPSS 10.0 software package. 
Results 
Validation study 
IMB assessed by Diascan® and direct dialysis quantification were highly significantly 
related (r=0.94; P<0.05; Figure 3.1). Dialysate conductivity of incoming dialysate 
assessed by the Integra® monitor was highly significantly related to dialysate 
conductivity assessed by the independent method (r=0.99; P<0.05). Moreover, 
dialysate sodium concentration and dialysate conductivity were highly significantly 
related (r=0.96; P<0.05).  
Isovolaemic dialysis 
All measurements were successful, except for one initial plasma conductivity 
measurement during DNa [140]. Pre-dialytic plasma conductivity and serum sodium 
concentrations are displayed in Tables 3.1 and 3.2. Pre-dialytic plasma conductivity 
was significantly related to pre-dialytic serum sodium (r=0.80; P<0.05).  


















Figure 3.1 Relation between IMB assessed by dialysate collection and Diascan®. 
  
 
Table 3.1 Plasma conductivity and ionic mass balance during isovolaemic dialysis, followed by 
haemodialysis combined with ultrafiltration. 
 Plasma conductivity (ms/cm) IMB (mmol) 
 A B C B C 
DNa[140] 14.21±0.31 14.18±0.22 14.11±0.16 33.6±31.5* 317.7±166.0 
DNa[144] 14.26±0.20 14.26±0.16 14.32±0.10# 11.3±26.0 238.7±116.4* 
DNa[ind] 14.24±0.22 14.22±0.21 14.24±0.24 24.8±21.7 276.9±116.2 
* P<0.05 compared with DNa[140] and DNa[ind]; # P<0.05 comparedwith pre-HD. Values as mean± SD. IMB, 
ionic mass balance; A, start dialysis; B, end isovolaemic dialysis (t=1 h); C, end dialysis combined with 
ultrafiltration. NB: a more positive IMB corresponds to a larger ionic removal. 
 
 
Table 3.2 Serum sodium, decline in blood volume, and ultrafiltration volume during isovolaemic dialysis 
followed by haemodialysis combined with ultrafiltration. 
 Serum sodium (mmol/l) BV (%) UF-vol (l) 
 A B C B C  
DNa[140] 139.1±2.0 139.5±2.8 139.4±1.3 -1.8±1.3 -8.6±4.6 1.5±1.0 
DNa[144] 139.2±1.9 138.6±2.5 140.2±1.5# -1.5±1.3 -7.4±3.7 1.4±0.9 
DNa[ind] 140.0±2.1 140.1±2.1 140.3±2.0 -1.9±1.3 -8.4±2.2 1.4±0.73 
 
 
Plasma conductivity and plasma sodium did not change significantly during 
isovolaemic dialysis (Tables 3.1 and 3.2). Although precision of the measurements was 
not formerly tested in this study, we got an impression on the precision. Plasma 
sodium levels at the start and after the end of isovolaemic dialysis were correlated, as 
were plasma conductivity measurements. The correlation coefficient was r=0.92 for 
46⏐Chapter 3 
plasma conductivity but only r=0.70 for plasma sodium levels (P<0.015), suggesting, 
but not proving, a higher precision of plasma conductivity measurements. 
Mean dialysate conductivity during DNa [ind] was 143±2.1 mmol/l. IMB differed 
significantly between the session with DNa [144] on the one hand and DNa [140] and 
DNa [ind] on the other, whereas DNa [140] and DNa [ind] were not significantly 
different (Table 3.1). IMB during isovolaemic dialysis with DNa [144] and DNa [140] 
was significantly related to the pre-dialytic plasma conductivity (r=0.97 and r=0.81; 
P<0.05) (Figures 3.2A and 3.3A), and to a somewhat lesser degree, to the pre-dialytic 
serum sodium concentration (r=0.83 and r=0.61; P<0.05) (Figures 3.2B and 3.3B). A 
negative IMB, indicating net ionic influx from dialysate to patient, occurred when the 
pre-dialytic serum sodium concentration was more than 5 mmol/l below the dialysate 
sodium concentration (Figures 3.2B and 3.3B). The relative blood volume declined 
slightly during all treatment sessions without significant differences between the 
sessions (Table 3.1). There was no significant relation between the change in blood 
volume and IMB during isovolaemic dialysis with either treatment session.  
 












Figure 3.2 (A) Relation between pre-dialytic plasma conductivity and IMB during isovolaemic dialysis 
(HD) with a dialysate sodium concentration of 140 mmol/l (DNa [140]). (B) Relation between 
pre-dialytic serum sodium and IMB during isovolaemic dialysis (HD) with a dialysate sodium 
concentration of 140 mmol/l (DNa [140]). 
Ultrafiltration combined with haemodialysis 
The mean ultrafiltration volume was comparable between the three treatment 
sessions (Table 3.2). 
Serum sodium increased significantly during DNa [144] but not during the other 
treatment modalities (Table 3.2). Moreover, IMB was significantly less positive during 
DNa [144], indicating less ionic removal, compared with DNa [140] and DNa [ind] 
(P<0.05) (Table 3.2 and Figure 3.4). IMB was significantly related to ultrafiltration 
volume during both DNa [140] (r=0.87), DNa [144] (r=0.81), and DNa [ind] (r=0.64; all 
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P<0.05). During DNa [140], but not during the other treatment sessions, IMB was 
significantly related to pre-dialytic plasma conductivity (r=0.59; P<0.05). 
 





Figure 3.3 (A) Relation between pre-dialytic plasma conductivity and IMB during isovolaemic dialysis 
(HD) with a dialysate sodium concentration of 144 mmol/l (DNa [144]). (B) Relation between 
pre-dialytic serum sodium and IMB during isovolemic dialysis (HD) with a dialysate sodium 



















Figure 3.4 IMB during ultrafiltration combined with haemodialysis (UF+HD) with different dialysate 
sodium concentrations. DNa [140], dialysate sodium 140 mmol/l; DNa [144], dialysate sodium 
144 mmol/l; DNa [ind], individualized dialysate sodium. Box indicates the 25th–75th 




The decline in relative blood volume (Table 3.2 and Figure 3.5) did not differ between 
the three treatment sessions. However, daily inter-dialytic weight gain following the 
treatment session was significantly higher after DNa [144] (0.66±0.33 kg/day) 
compared with DNa [140] (0.57±0.33 kg/day; P<0.05), whereas the difference with 








Figure 3.5 Decline in blood volume (BV) during ultrafiltration combined with haemodialysis (UF+HD) with 
different dialysate sodium concentrations. DNa [140], dialysate sodium 140 mmol/l; DNa 
[144], dialysate sodium 144 mmol/l; DNa [ind], individualized dialysate sodium. Box indicates 




The change in systolic blood pressure during the entire dialysis session (which was 
12.7±21.0 mmHg during DNa [140], 0.0±15.3 mmHg during DNa [144], and 5.9±17.4 
mmHg during DNa [ind]) did not differ significantly between the different dialysis 
sessions, although it tended to be higher during DNa [140] compared with DNa [ind] 
(P=0.08). Also, the decline in diastolic blood pressure (which was -5.6±12.6 mmHg 
during DNa [140], -7.5±14 mmHg during DNa [144], and -2.4±9.4 mmHg during DNa 
[ind]) did not differ significantly between the different dialysis sessions.  
When patients with a pre-dialytic serum sodium concentration below 140 mmol/l or 
higher or equal to 140 mmol/l were analysed separately (n=5), IMB was significantly 
higher during DNa [ind] compared with DNa [140] in patients with a pre-dialytic serum 
sodium concentration below 140 mmol/l (Figure 3.6) (324±87 vs 228±127 mmol; 
P<0.05) whereas the decline in relative blood volume did not differ significantly 
(-9.8±1.6 vs -7.8±2.3%; P=NS). In contrast, in patients with a pre-dialytic serum sodium 
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concentration higher or equal to 140 mmol/l (n=8), IMB was significantly lower during 
DNa [ind] compared with DNa [140] (254±123 vs 350±178 mmol; P<0.05) (Figure 3.5) 
whereas also in these patients, the decline in relative blood volume did not differ 
significantly (-7.1±1.8 vs -8.1±3.11%).  
 













Figure 3.6 IMB during ultrafiltration combined with haemodialysis during dialysis with dialysate sodium 
concentrations of 140 mmol/l (DNa [140]) and individualized dialysate sodium (DNa [ind]) in 
patients with a pre-dialytic serum sodium concentration <140 (left) and ≥140 mmol/l (right). 
Box indicates the 25th–75th percentile range (line in box, median). Capped bars indicate the 
10th–90th percentile range. 
Discussion 
The main findings of the present study are first, the large difference in ionic mass 
balance between haemodialysis with DNa [140] and DNa [ind] on the one hand and 
DNa [144] on the other, in combination with the small and non-significant difference 
in blood volume preservation between these modalities; secondly, the strong relation 
between pre-dialytic plasma sodium and plasma conductivity with ionic mass balance, 
which explains the diffusive ionic influx during isovolaemic dialysis in patients with low 
pre-dialytic plasma sodium levels; thirdly, the increased ionic removal during DNa [ind] 
in patients with low pre-dialytic plasma sodium levels and reduced ionic removal in 
patients with high pre-dialytic plasma sodium levels despite the absence of differences 
in blood volume preservation compared with DNa [140]. 
Ionic mass balance measurements by Diascan® appears to be suitable in detecting 
ionic changes during dialysis, as shown by the good agreement between Diascan® 
measurements and conductivity measurements in spent dialysate obtained during an 
entire dialysis session. As a result of the abundance of sodium ions in both dialysate 
and plasma, it is likely that IMB reflects predominately sodium balance during dialysis. 
It should, however, be mentioned that due to rapid changes in pH, chloride, and 
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bicarbonate, the relation of conductivity measurements to sodium balance may 
deviate slightly during dialysis. Moreover, in the present study, the relation between 
both plasma sodium and plasma conductivity levels was not completely linear. We 
believe, however, that this phenomenon might be due to a lack of precision of sodium 
measurements, as shown by the greater reproducibility of plasma conductivity 
measurements compared with plasma sodium levels, presented in the results section 
on isovolaemic dialysis. Moreover, the relation between pre-dialytic plasma 
conductivity measurements and IMB in the present study was far stronger than that 
obtained using plasma sodium measurements. The possible lack of preciseness of 
plasma sodium determination raises some doubt on the usefulness of monitoring 
plasma sodium levels in order to detect differences in ionic removal between various 
treatment modalities11. 
Both during isovolaemic dialysis, as well as during haemodialysis combined with 
ultrafiltration, a significant difference in ionic mass balance was observed between 
DNa [144] compared with DNa [140] and DNa [ind], indicating less ionic removal 
during DNa [144]. Moreover, plasma sodium levels increased significantly during DNa 
[144], but not during the other treatment modalities. The mean difference in 
measured ionic mass balance between high and standard sodium dialysate was 
approximately 90 mmol during an entire dialysis session, in theory corresponding to 
2000 mg of sodium, thus the entire recommended daily sodium intake of a dialysis 
patient. The long-term clinical significance of this phenomenon cannot be elucidated 
from the present study but may not be negligible in view of the strong arguments for a 
relation between sodium, hypertension, and cardiac abnormalities in dialysis 
patients4,5. Indeed, even inter-dialytic weight gain was higher after treatment with 
DNa [144]. However, only three single treatments were compared in this study and 
effects of different dialysate sodium prescription on ionic mass balance need to be 
repeated in more long term studies. Remarkable was the small and non-significant 
difference in blood volume preservation between the three treatment modalities. 
Nevertheless, in this stable group of dialysis patients, the decline in systolic blood 
pressure tended to be somewhat higher during DNa [140] compared with DNa [144].  
The net diffusive ionic influx during DNa [140] in patients with low pre-dialytic plasma 
sodium levels is a phenomenon not often described in the literature, but is in line with 
earlier experimental data and theoretical considerations11-13. In the present study, 
diffusive ionic influx was observed when the plasma sodium concentration was 
approximately 2 mmol/l lower than the dialysate sodium concentration. Factors 
influencing diffusion between dialysate and plasma are complex and include the 
sodium concentration in plasma water, the Donnan effect, and the formation of 
complexes of sodium ions with anions in plasma water and dialysate11-13 ,as described 
in the Introduction.  
Individualization of the dialysate in the present study was achieved by adjusting 
dialysate conductivity (which corresponds to DNa7) to the pre-dialytic plasma 
conductivity of the patient. This approach was performed because (effective) plasma 
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conductivity measured by Diascan® is only related to the concentration of sodium ions 
which are free to diffuse and not trapped by the Donnan effect7. Individualization of 
DNa appeared predominantly relevant in patients with low pre-dialytic sodium levels, 
because in these patients, an increased ionic removal was achieved compared with 
DNa [140] whereas the decline in blood volume did not differ significantly. 
Nevertheless, the mean observed difference of approximately 2% might again be 
relevant in some patients. Therefore, it would certainly seem judicious to apply blood 
volume measurements if individualization of DNa is to be applied in hypotensive-
prone dialysis patients with low pre-dialytic plasma sodium levels. 
In the patients with higher pre-dialytic sodium levels, ionic removal was actually less 
during DNa [140] compared with DNa [ind] whereas again the decline in blood volume 
was not apparently different from DNa [140]. 
Drawbacks of the study are first the relatively small number of included patients, 
although this does not appear to have influenced the primary goal of the study, i.e. to 
assess IMB during different dialysate [Na] concentrations. Moreover, because the 
main objection was to study IMB and blood volume preservation during different 
dialysate sodium concentrations, stable haemodialysis patients were included. Further 
studies should also address the feasibility of individualized sodium concentrations of 
the dialysate in hypotension-prone dialysis patients. 
Moreover, several patients still have residual renal function, which might have 
interfered with the influence of dialysate sodium prescription on inter-dialytic weight 
gain. 
In conclusion, comparing three single sessions differing in dialysate sodium 
concentration, a relatively large difference in IMB, which may amount to the entire 
recommended daily sodium intake of a dialysis patient, was observed between DNa 
[144] on the one hand and DNa [140] and DNa [ind] on the other despite a nearly 
comparable blood volume preservation. In patients with a low pre-dialytic plasma 
sodium concentration, net diffusive ionic influx from the dialysate to the patient may 
occur during a fixed DNa. In patients with a low pre-dialytic plasma sodium 
concentration, individualization of dialysate sodium led to an improved ionic removal 
in patients, apparently without large implications for blood volume preservation 
during dialysis.  
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In this study, variations in plasma conductivity (PC), as a surrogate marker of plasma sodium, as well as its 
relation with intra-dialytic ionic mass balance (IMB) and  blood pressure were assessed in 73 patients. PC 
and IMB were retrieved on a treatment-to-treatment basis during a 6-months period. Dialysate sodium was 
140 mmol/l. 4070 treatments were analyzed. 
 
Methods and Results 
Mean coefficient of variation for pre-dialytic PC was 1.3%, and mean intra-individual range in pre-dialytic PC 
measurements during the six months follow-up period was 0.9 mS/cm [~ plasma sodium 9 mmol/l]. Pre-
dialytic PC was related to both diffusive and total IMB (r=0.91; P<0.001 and r=0.35; P<0.01). The average 
diffusive IMB over a six-month period was negative in 33% of patients, and the average PC increased during 
dialysis in 14% of patients. Averaged pre-dialytic PC was significantly related to systolic blood pressure 
(r=0.35; P<0.01), whereas within patients, pre-dialytic systolic blood pressure was significantly different 
between treatments with the lowest and highest pre-dialytic PC (139±24 versus 147±21 mmHg; P<0.05). 
 
Conclusion 
Concluding, depending on PC, diffusive ionic transfer from dialysate to patient may occur in a significant 
percentage of patients using a dialysate sodium concentration of 140 mmol/l. Variations in PC are related to 
blood pressure, which might suggest a volume-independent effect of sodium.  
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Introduction 
Volume and sodium overload in dialysis patients are related to hypertension, edema 
and left ventricular dilatation1. Preliminary data suggest that, apart from volume, 
sodium might also have an independent effect on blood pressure regulation in dialysis 
patients2,3.  
During dialysis, the main determinant of sodium removal during dialysis is the 
ultrafiltration volume (convective mass transfer). However, also the contribution of 
diffusive mass transfer of sodium may be significant4. As such, the prescription of the 
dialysate sodium concentration has an important effect on sodium balance during 
dialysis. With the advent of dialysate conductivity monitoring, it has become possible 
to approximate sodium fluxes during dialysis by means of the assessment of intra-
dialytic ionic mass balance (IMB), as well as plasma conductivity (PC) as a surrogate of 
plasma sodium4-8. These developments offer the opportunity to study sodium balance 
in more detail. The main advantage of PC is, that it can be used on a treatment-to-
treatment basis without need for blood sampling. 
Whereas previous studies have focused on the effect of modifications of dialysis 
treatment, such as sodium profiling4,5,9,10 in relatively small groups of patients, little is 
known about sodium balance on a treatment to treatment basis during dialysis with 
standard sodium concentrations (e.g. 140 mmol/l) at facility level. One study showed 
an increase in plasma sodium during dialysis in a significant subset of patients with the 
use of a dialysate sodium concentration of 140 mmol/l11. Pre-dialytic plasma sodium 
levels are generally considered to be stable in dialysis patients, assuming a fixed 
sodium set-point in dialysis patients12,13, which may be of importance when dialysate 
sodium prescriptions are individualized. However, long term studies on sodium 
balance and variations in plasma sodium are scarce.  
The aim of the present study was to assess variations in PC, as a surrogate marker of 
plasma sodium on a treatment to treatment basis at facility level. Moreover, the 
relation of inter and intra-individual changes in PC with IMB, blood pressure, relative 
blood volume (RBV) and inter-dialytic weight gain was assessed. 
Methods 
Study protocol 
In the dialysis centre of Maxima Medical Centre Veldhoven, The Netherlands, 
treatment data on PC, IMB, and changes in RBV are automatically stored in a database 
on a treatment to treatment basis. Data were retrieved from this database for a 
consecutive period of 6 months in each patient, and were randomly collected in the 
period between august 2006 and November 2007. Moreover, in this database, pre- 
and post-dialytic BP and body weight are recorded. The study was carried out 
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according to the declaration of Helsinki and approved by the local institutional review 
board.  
Data from 73 chronic dialysis patients were recorded. Patient characteristics are 
displayed in Table 4.1. All patients were on thrice-weekly hemodialysis, except for two 
patients, who were treated with twice-weekly dialysis sessions. All patients were 
treated with Integra® (Hospal-Gambro, Mirandola, Italy) device, by which PC, IMB and 
changes in relative blood volume are automatically assessed and recorded. 
Polysulfone, low flux dialysis membranes (F8HPS®, Fresenius, Bad Homburg, Germany) 
were used. At the time of the study, prescription of the dialysate was: sodium 140 
mmol/l (conductivity 14.0 mS/cm), potassium 2.0 mmol/l, calcium 1.5 mmol/l, 
magnesium 0.5 mmol/l, bicarbonate 32 mmol/l, acetate 3.0 mmol/l and glucose 1 g/l. 
Setting of the dialysate conductivity of the dialysis machine was 14mS/cm. 
Temperature of the dialysate was 36°C. Patients were ultrafiltrated until their clinically 
determined dry weight. Fifteen patients were treated with the Hemocontrol® (Hospal-
Gambro) biofeedback module, for which also an equivalent dialysate conductivity of 
14.0 mS/cm was prescribed. 
 
Table 4.1 Patient characteristics. 
Age (years)  67 ± 16 
Male/Female  42 / 31 
Dry weight (kg)  70.2 ± 14 
Dialysis duration (hours)  3.9 ± 0.38 
Dialysis frequency (per week)  2.9 ± 0.3 
Residual Glomerular filtration rate (ml/min)  1.1 ± 1.8 
 
Ionic mass balance 
Intra-dialytic IMB was estimated by Diascan® (Hospal-Gambro) integrated in the 
Integra® dialysis module8,14. In short, Diascan® measures IMB by constant 
measurement of the conductivity in the dialysis outlet (Cdout) and inlet (Cdin). IMB is 
reported directly by the dialysis module. By convention, and also as such reported by 
the Integra® device, a positive IMB reflects net ionic removal from the patient, a 
negative IMB means net ionic transfer from dialysate to the patient6. Diffusive IMB 
was assessed by the following formula:  
diffusive IMB = total IMB – [(mean PC x 10.4)-9.57] x UF volume6. 
Validation of IMB measurements  
In 22 patients, direct dialysis quantification by Quantiscan® was performed during a 
single dialysis session. Quantiscan® continuously samples a small amount of the spent 
dialysis fluid. Electrolytes were assessed in duplicate in the spent dialysis fluid: sodium 
 Variations in pre-dialytic plasma conductivity in dialysis patients⏐57 
(flame photometry and indirect ionometry), potassium, calcium, phosphate, 
bicarbonate and chloride. Sodium balance was assessed as follows:  
[Cout x Vout] - [Cin x Vin] 
Cout and Cin are the sodium concentration in spent and fresh dialysate, respectively. 
Vout and Vin are the volume of spent and incoming dialysate.  
Vout  is calculated as (dialysate flow rate (ml/min) + ultrafiltration rate (ml/min)) x 
dialysis time (min)  
and Vin as dialysate flow rate (ml/min) x dialysis time (min). The same procedure was 
followed for the other ions. 
Plasma conductivity 
PC was measured and reported directly by Diascan® by measuring dialysance (D) in 
combination with measurements of Cdout and Cdin according
 to the formula:  
PC = [Cdout – (1 – D/Qdin) x Cdin]/(D/Qdin) 
D is assessed every 30 min by measuring the increase in Cdout
 after a temporary 
increase in Cdin by 1 mS/cm according to the
 formula:  
D = Qdin + Qf x [1 – (Cdout1 – Cdout2)/(Cdin1 –
 Cdin2)] 
1 and 2 indicate, respectively, the measurements before and after the temporary 
increase in Cdin
4,14, Qdin  = dialysate flow at inlet, Qf = ultrafiltration rate
   
 
Plasma sodium 
Plasma sodium levels were assessed before dialysis, approximately once monthly, by 
indirect ionometry (Vitros 950®). Plasma sodium levels were available in 332 
treatments. The relation between PC and plasma sodium given in the literature is:   
 Plasma sodium = (PC x 10.4)-9.57 6,7.  
 
Relative blood volume, blood pressure and residual GFR 
Changes in relative blood volume were measured continuously by continuous optical 
assessment of changes in haemoglobin during the dialysis session (Hemoscan®, 
Hospal-Gambro). Blood pressure was taken as part of the clinical routine in sitting 
position just prior to the start of dialysis treatment. Body weight was measured, as 
part of the clinical routine, on a gravimetric scale. Residual GFR was assessed by inter-
dialytic urine collections as the mean of urea and creatinine clearance. 
Data analysis 
Intra- and inter-individual variations in PC are reported by means of the range, 
standard deviation, and coefficient of variation. The relation between pre-dialytic PC, 
IMB, relative blood volume, interdialytic weight gain and blood pressure was assessed 
by correlation analysis (Pearson’s r). Measurements during the 6 months period were 
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also pooled for each patient, and the mean of these data was used for analysis. 
Multiregression analysis was used where necessary. Regarding intra-individual 
variations, pre-dialytic blood pressure and interdialytic weight gain were compared 
between the session with the highest and lowest value of PC and analyzed using a 
paired student-t test. Correction for ultrafiltration volume and timing of the dialysis 
shift (after longest or short dialysis interval) was performed using univariate analysis 
with lowest or highest plasma conductivity as fixed factor and timing of dialysis shift 
and ultrafiltration volume as covariates.  
Results 
In total, 4070 measurements were retrieved in 73 patients. The mean number of 
treatment analysed was 56 [range 45 to 63 treatments]. Missing data were amongst 
others, the result of technical problems with the data management tool. The mean of 
the pooled data collected during the 6 months period for the patient is summarized in 
Table 4.2, separately presented for patients on Hemocontrol and standard dialysis 
treatment.  
 
Table 4.2 Summary of parameters (6 months data pooled for each patient). 
 Standard dialysis (n=58) Hemocontrol (n=15) 
Pre-dialytic PC (mS/cm)  14.19 ± 0.22  14.39 ± 0.14 
Post-dialytic PC (mS/cm)  14.06 ± 0.09  14.07 ± 0.06 
Total IMB (mmol/treatment)  342.8 ± 140.8  463.8 ± 57.6  
Diffusive IMB (mmol/treatment)  26.8 ± 64.5  95.6 ± 35.8 
Inter-dialytic weight gain (kg)  2.5 ± 1.0  2.7 ± 0.5 
Decline in relative blood volume (%)  -7.9 ± 2.7  -7.9 ± 2.3 
Pre-dialytic systolic BP (mmHg)  143.2 ± 18.4  153.2 ± 15.3 
Pre-dialytic diastolic BP (mmHg)  78.6 ± 11.3  81.0 ± 0.9 
% patients with negative IMB 32.9 0 
% patients with increasing PC 13.7 0 
PC=plasma conductivity (mS/cm); IMB=ionic mass balance (mmol/treatment); BP=blood pressure (mmHg) 
 
Diffusive mass balance was 18.3±16.7% of convective mass balance. Whereas total 
IMB was positive (indicating net ionic transfer from the patient to the dialysate) in all 
patients using the pooled data, the averaged diffusive IMB was negative (indicating 
diffusive ionic transfer from dialysate to patient) in 33% of patients. In 14% of 
patients, the averaged PC increased during dialysis. As shown in Table 4.3, the only 
parameter which distinguished between patients with respective negative or positive 
diffusive IMB, or an increase or decrease in PC during dialysis, was the pre-dialytic PC.  
For intra-individual variations in pre-dialytic PC, the coefficient of variation during the 
6 months follow-up period was 1.3%. For post-diaytic PC, the coefficient of variation 
was 1.0%. The mean (14.31±0.19 versus 14.21±0.23) and coefficient of variation [1.2 
 Variations in pre-dialytic plasma conductivity in dialysis patients⏐59 
vs 1.3%] of pre-dialytic PC was not significantly different between patients with (n=15) 
or without diabetes mellitus (n=58)  
 
 
Table 4.3 Differences between patients with a (mean averaged) negative of positive diffusive IMB and 
increase or decrease in PC during dialysis. 
 IMB<0 IMB≥0  PC ↑ PC ↓  
 Mean±SD Mean±SD P value Mean±SD Mean±SD P value 
 24 49  10 63  
Age 70.7±13.6 66.7±16.9 NS 69.0±15.5 67.1±16.2 NS 
Diabetes Mellitus n=4 (17%) n=11 (22%) NS n=0 n=15 (24%) 0.08 
Pre-dialytic PC (mS/cm) 14.00±0.18 14.34±0.14 <0.001 13.83±0.11 14.29±0.15   <0.001* 
Inter-dialytic weight gain (kg) 2.6±1.0 2.5±0.8 NS 2.8±1.0 2.5±0.9 NS 
Mean values (SD) are presented for continues variables. Significant, P<0.05. 
IMB<0 means net diffusive ionic transport from dialysate to patient. PC=plasma conductivity (mS/cm); 
IMB=ionic mass balance (mmol/treatment). 
 
 
Within patients, pre-dialytic PC was 13.78 mS/cm±0.29 before the treatment with the 
lowest pre-dialytic PC and 14.65 mS/cm±0.25 before the treatment in which the 
highest pre-dialytic PC was recorded. The intra- and inter-patient variations in pre-
dialytic PC can also be observed in Figure 4.1A and 4.1B. The variation in the CV of 
pre-dialytic PC is shown in Figure 4.1C.   
Although the observation period was not designed to assess seasonal variations in 
detail, we observed a significantly difference between the various seasons with the 
lowest values in autumn (14.21±0.28 mS/cm), followed by summer (14.22±0.28 
mS/cm), winter (14.25±0.30) and spring (14.27±0.28 mS/cm) (p<0.001). Regarding the 
timing of the dialysis shift, we also compared pre-dialytic PC between treatments after 
the longest shift, and the other treatments. No significant difference in PC was 
observed: 14.24±0.29 before the longest shifts and 14.25±0.29 before the other shifts.  
The variation in post-dialytic PC was less as compared to pre-dialytic PC . Mean SD for 
post-dialytic PC was 0.09 mS/cm. Post-dialytic PC was 13.85 mS/cm±0.19 after the 
treatment with the lowest pre-dialytic PC and 14.30 mS/cm±0.20 after the treatment 


















Figure 4.1A Inter and intra-dialytic variation in pre-dialytic plasma conductivity (mean ± SD).  

















Figure 4.1B Inter and intra-dialytic variation in post-dialytic plasma conductivity (mean ± SD).  
 The horizontal line depicts a PC of 14.0 mS/cm. PC=plasma conductivity (mS/cm) 





















Figure 4.1C Coefficient of variation for plasma conductivity: frequency and distribution in patients  
 PC=plasma conductivity (mS/cm) 
 
Relation between PC, IMB and hemodynamic parameters 
In the 4070 measurements, pre-dialytic PC was significantly related to diffusive IMB 
(r=0.82; P<0.001) (Figure 4.2). The same held true for diabetic patients (n=15), which 
were analyzed in a subgroup (r=0.86; P<0.001). Total and diffusive IMB, as well as 
inter-dialytic weight gain were not significantly different between patients with or 
without diabetes mellitus. 
The mean averaged PC during the 6 months period in the 73 patients was significantly 
related to total (r=0.37; P<0.01) and diffusive IMB (r=0.91; P<0.001) ,as well as to the 
change in PC during dialysis (r=-0.85; P<0.001). Total IMB was strongly related to 
ultrafiltration volume (r=0.88). Pre-dialytic PC was significantly related to pre-dialytic 
systolic blood pressure (r=0.35; P<0.01) [Figure 4.3A], but not to diastolic blood 
pressure (r=0.1; P=NS) or interdialytic weight gain in the period before (r=-0.09; 
P=NS). Using multiregression analysis, the relation between pre-dialytic systolic BP 
and pre-dialytic PC (β=0.37; P=0.002) was independent of inter-dialytic weight gain, 
and the number of antihypertensive agents used (β=0.14; P=NS). Although the 
relation between pre-dialytic PC and diffusive IMB was comparable (r=0.84; P<0.001) 
in the subgroup of patients on Hemocontrol®, diffusive IMB was positive in all patients 

















Figure 4.2 Relation between pre-dialytic PC and diffusive IMB  
 PC=plasma conductivity (mS/cm);  
 IMB=ionic mass balance (mmol/treatment) 
 
Intra-patient variations in pre-dialytic PC 
When analyzing the effect of intra-patient variations of PC, significant differences in 
IMB, pre-dialytic systolic (Figure 4.3B) and diastolic blood pressure were observed 
between the treatments with the lowest and highest pre-dialytic PC, whereas 
interdialytic weight gain (in the period before the highest and lowest PC) were not 
significantly different (Table 4.4). There was no significant relation between the 
absolute difference in blood pressure and the corresponding difference in PC between 
both treatments.  
 
Table 4.4 Intra-patient differences between treatments with the highest and lowest pre-dialytic PC. 
 Lowest PC Highest PC  
Pre-dialytic PC (mS/cm) 13.78±0.29 14.65±0.25 <0.001 
Post-dialytic PC (mS/cm) 13.85±0.19 14.30±0.20 <0.001 
Total IMB (mmol/treatment) 237.3±163.8 511±165.9 <0.001 
Diffusive IMB (mmol/treatment) -84.7±66.7 132.4±98.3 <0.001 
Inter-dialytic weight gain (kg) 2.4±1.1 2.7±1.0 NS 
Decline in relative blood volume (%) -8.1±3.5 -7.7±3.6 NS 
Pre-dialytic systolic BP (mmHg) 138.6±23.8 147.4±21.2 <0.05 
Pre-dialytic diastolic BP (mmHg) 75.2±13.3 81.0±13.6 <0.01 
PC=plasma conductivity (mS/cm); IMB=ionic mass balance (mmol/treatment); BP=blood pressure (mmHg) 
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There were no significant differences in inter-dialytic weight gain (2.6±1.0 versus 
2.5±1.0 l), systolic (148.6±25.1 versus 145.5±24.3 mmHg) or diastolic blood pressure 
(80.5±13.5 versus 79.6±14.4 mmHg) in the period after the highest and lowest pre-
dialytic PC.  
 
When using univariate analysis with correction for covariates, the difference between 
the treatments with lowest or highest pre-dialytic PC value and pre-dialytic systolic 
blood pressure remained significant (F=5.9; P<0.05) independent of the season 
(F=8.38; P<0.01), timing of the dialysis shift [after long or short interval](F=0.27; P=NS) 
and interdialytic weight gain (in the period before the lowest or highest PC) (F=3.03; 
P=0.08). The same held true for the difference in pre-dialytic diastolic blood pressure 
between the treatments with the highest and lowest pre-dialytic PC (F=6.91; P=0.01) 
when corrected for inter-dialytic weight gain (F=4.13; P<0.05), timing of dialysis shift 
(F=0.86; P=NS) or season (F=2.91; P=0.09).  
 
Plasma sodium: variation and relation with PC and IMB 
Mean pre-diaytic plasma sodium was 140.0±3.4 mmol/l. Mean intra-individual 
coefficient of variation was 1.4%. The mean difference between the lowest and 
highest plasma sodium concentration was 4.6 mmol/l. 
In the present study, the relation between pre-dialytic plasma sodium and PC was 
highly significant (r=0.77; P<0.001) [Figure 4.4A]. The regression equation between 
plasma sodium and PC was as follows:  
plasma sodium = 26.98+7.94*PC  
(in which a PC of 14.0 mS/cm would correspond to a plasma sodium of 138.1 mmol/l.  
Using the data of the 332 treatments for which plasma sodium was available, pre-
dialytic plasma sodium was significantly related to diffusive IMB (r=0.57; P<0.001) and 
total IMB (r=0.26; P<0.001)  (Figure 4.4B).  
Validation study: relation between  IMB and sodium balance 
As displayed in Figure 4.5A a highly significant relation was observed between IMB 
and sodium balance (using flame photometry) based on direct dialysis quantification 
(r2=0.98). The disagreement in absolute values appeared to increase at higher levels 
of IMB, as shown in Figure 4.5B However, the F-vale for the regression equation 
between sodium balance and IMB was very high (F=307.6), with the following 
equation:  
Sodium balance (mmol)=57 + 1.29 x IMB.  
Using indirect ionometry to determine sodium, the correlation became somewhat less 
strong (r=0.91), but the mean difference between both methods was also somewhat 
less as compared to the flame photometry measurements (76±202 mmol). Whereas in 
multiregression analysis, the relation between IMB and sodium balance was highly 
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significant, the balance of the other ions such as potassium, chloride, bicarbonate and 
calcium was not significantly related to IMB. 
 
 












Figure 4.3 A: Relation between pre-dialytic PC and pre-dialytic systolic BP (mean of pooled data) 
 B: Intra-patient difference in systolic BP between treatments with the lowest and highest PC  



















Figure 4.4A Relation between pre-dialytic plasma sodium and plasma conductivity 
 PC=plasma conductivity (mS/cm) 
 
















Figure 4.4B Relation between pre-dialytic plasma sodium and diffusive ionic mass balance. 
 IMB=ionic mass balance (mmol/treatment) 
 
 












Figure 4.5 A: Relation between IMB by Diascan® and sodium balance by flame photometry in direct  
  dialysis quantification.  
 B: Agreement between IMB by Diascan® and sodium balance by flame photometry in direct  
  dialysis quantification.  
 IMB= Ionic mass balance (mmol/treatment); Sodium balance (difference between dialysate 





This study shows that both intra- and inter-individual variations in PC, which was used 
as a surrogate for plasma sodium, have a significant effect on IMB (as a surrogate 
marker for sodium balance) during dialysis. With a dialysate sodium concentration of 
140 mmol/l, in a significant percentage of patients diffusive ionic mass transfer from 
dialysate to patient was observed, whereas PC increased during dialysis in a lesser 
percentage of patients. Both inter- and intra-individual variations in pre-dialytic PC 
were related to pre-dialytic blood pressure, independent of interdialytic weight gain 
and thus appear to be of physiologic relevance.   
In agreement with earlier studies in dialysis patients, we observed a significant inter-
individual variation in pre-dialytic PC, as a surrogate for plasma sodium. Moreover, 
also significant intra-individual variations in PC were observed. In 10 nondiabetic 
dialysis patients whom were followed for 12 months, Flanigan observed a variation in 
plasma sodium concentrations of approximately 2%11. This would appear in 
agreement with the mean coefficient of variation of 1.3% of PC in the present study, 
which is in agreement with data from the normal population in the literature and 
likely reflects for the largest part “real” intra-individual and not method variation15. 
However, the mean intra-individual difference in PC measurements between the 
lowest and highest PC measurements during the 6 months follow-up period was 
0.9 mS/cm, corresponding to a plasma sodium concentration of ±9 mmol/l. This 
observation shows that during a follow-up period of 6 months, relatively large intra-
patient variations in PC may occur. Although some of these values may be outliers, 
they still might have pathophysiologic relevance due to the relation with blood 
pressure and IMB. We were not able to provide a definite explanation for the 
variations in PC. He et al. showed an effect of dietary sodium intake on plasma sodium 
levels16 . We also noted some seasonal variation in PC, although the study was not 
specifically designed for this purpose. The seasonal variation in PC is in agreement 
with the data of Chen17 in peritoneal dialysis patients.  
 
The variation in PC is in agreement with earlier observations on plasma sodium. In the 
study of Flanigan, the variation in pre-dialytic plasma sodium concentrations was 
often in the order of 5 mmol/l during the 12 month follow-up period. In the present 
study, the mean range in plasma sodium levels, which were however only available on 
a monthly basis, was 4.6 mmol/l.  
 
Various authors suggested the presence of an individual sodium setpoint in dialysis 
patients, which may be used as a tool for individualized sodium prescription6,13,18. 
Data on the presence of a fixed sodium setpoint in individual dialysis patients are 
somewhat conflicting. Whereas some authors did not observe change in pre-dialytic 
plasma sodium concentration after changing dialysate sodium prescription18-20, we 
and others observed a change in pre-dialytic PC or plasma sodium after a change in 
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dialysate sodium prescription5,9,21. The reason for this discrepancy is not clear, but it 
might also be hypothesized that the patients who experience an increase in plasma 
sodium level after an increase in dialysate sodium, managed to comply with the 
habitual fluid restriction, at the cost of increased thirst. The results of the present 
study suggest that plasma sodium levels, when used as a guide for individualisation of 
dialysate sodium prescription, should be examined on a regular basis. However, it 
cannot be excluded that variations in other ions, such as potassium and bicarbonate, 
also play a role in the observed variations in PC, although e.g. potassium in a 
concentration of 2 mmol/l contributes only for 0.5% to dialysate conductivity 8. 
 
Pre dialytic PC was a strong determinant of diffusive IMB, and in a lesser degree to 
total IMB, during dialysis. Using the mean of 6 months, diffusive IMB was negative in 
nearly 33% of dialysis patients, suggesting diffusive ionic influx from dialysate to the 
patient. Due to the strong correlation between IMB and sodium balance6 this might 
suggest net diffusive sodium influx from dialysate to the patient. However, these 
results should be interpreted with some caution given the fact that sodium removal 
may be somewhat underestimated by IMB6. Surprisingly, we did not observe a mean 
diffusive ionic influx in the patients treated with Hemocontrol®, which is likely due to 
the fact that mean PC was higher in these patients. For this observation, we do not 
have a good explanation. In an earlier randomized crossover study, we observed no 
difference in IMB of PC when patients were treated with either Hemocontrol® or 
standard dialysis5.  
 
In the present study, we compared IMB measurements to sodium balance using direct 
dialysis quantification. A highly significant relation was observed between IMB and 
direct dialysis quantification with sodium measurements assessed by flame 
photometry.  
However, also in our study, some underestimation of sodium removal by IMB was 
observed. Mass balances of other ions, such as potassium or bicarbonate, were not 
significantly related to IMB. Access recirculation, which theoretically could also affect 
IMB measurements was not assessed in the study. However, given the highly 
significant regression model between IMB and sodium balance, we believe IMB might 
be used as a indicative marker for sodium balance, taking the caveats into account. In 
an earlier study, large differences in IMB were observed between treatments which 
only differed in dialysate sodium prescription4.  
 
Averaged over the 6-months period, PC increased during dialysis in 14% of patients, 
which is an additional argument for diffusive sodium influx in a significant minority of 
dialysis patients. In general, diffusive ionic influx appeared to occur when pre-dialytic 
PC was below 14.25 mS/cm (roughly corresponding to a plasma sodium concentration 
of 140 mmol/l)22,23. However, given the slight  underestimation of sodium removal by 
IMB and the possible effect of other ions on IMB, the extrapolation of these findings 
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should be interpreted with some caution. Interestingly, the number of patients in 
which PC increased during dialysis was less compared to the number of patients with 
diffusive ionic influx. Although the reason for this observation is not entirely clear, this 
might be due to the fact that to decrease in PC may to some degree, also be due to 
lowered plasma levels of other ions. 
Although far less treatments in which pre-dialytic plasma sodium levels were 
observed were available for analysis, diffusive ionic influx (negative IMB) from 
dialysate to patient appeared to occur when plasma sodium concentration was below 
140 mmol/l, which would appear in basic agreement with the relation between PC 
and diffusive IMB discussed above.    
 
Due to the strong influence of ultrafiltration on ionic mass removal, net ionic mass 
removal was observed in nearly all patients. Admittedly, the clinical importance of the 
diffusive ionic mass transfer cannot be elucidated from the present study. Lowering of 
dialysate sodium from 141 to 138 mmol/l at a facility level resulted in a small 
improvement in BP control without an increase in hypotensive episodes24. 
Individualisation of dialysate sodium concentration in patients with lower pre-dialytic 
plasma sodium concentrations was shown to have additive value in terms of blood 
pressure control18.  
 
Apart from the effects on diffusive IMB, intra-individual differences in PC might be of 
physiologic relevance, given the significant relation with pre-dialytic systolic BP. This 
relation was independent from interdialytic weight gain, suggesting an independent 
pressor effect of plasma sodium, although these observations should be confirmed in 
future studies as a causal relationship cannot be deduced from the present 
observational data. Proposed pathophysiological mechanisms for this relation remain 
hypothetical, and include, among others, an effect of sodium on sympathetic activity, 
nitric oxide metabolism, or digoxin-like factors24,25. The effect of seasonal variations, 
which also might influence blood pressure levels, did not explain the relation between 
PC and blood pressure in our study. As plasma sodium may be decreased in patients 
with heart failure, one could argue however that also differences in cardiac function, 
leading to low pre-dialytic systolic BP, could also provide an explanation of these 
findings. We are not able to provide echocardiographic examinations for all patients 
during the study period. However, differences in cardiac function are unlikely to 
explain the effect of intra-individual differences in PC on blood pressure: both pre-
dialytic systolic BP and diastolic BP were significantly different between treatments 
with the highest and lowest pre-dialytic PC.  
 
An important advantage of the present study is that it comprises a large group of 
unselected patients, in which measurements of PC, IMB, and relative blood volume 
were available for every treatment within a 6 months observation interval. A major 
limitation is the observational nature of the study. Another drawback of the study is 
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the fact that PC, and not plasma sodium measurements were used. The use of PC as a 
surrogate for plasma sodium appears justified in view of the strong relation between 
PC and plasma sodium7, and due to the fact that measurements can be obtained 
automatically from the software of the dialysis module without the need for blood 
sampling during every dialysis treatment. From a theoretical point of view, both 
plasma sodium and PC are surrogate markers of plasma osmolality, which is the 
driving force for thirst. In the present study, plasma sodium and PC were also highly 
significantly related. However, in view of the possible (minor) contributions of other 
ions to PC, our findings should be interpreted with caution.  
Another drawback of the study is the absence of detailed information on volume 
status of the patient, alimentary intake, and the absence of ambulatory blood 
pressure measurements.  
Concluding, diffusive ionic mass transfer is strongly dependent upon pre-dialytic PC. A 
dialysate sodium concentration of 140 mmol/l was associated with diffusive mass 
transfer from dialysate to patient, and a rise in PC in a significant percentage of 
patients. Both intra- and inter-patient variations in PC are significantly related to pre-
dialytic systolic blood pressure, independent of interdialytic weight gain, which might 
suggest a volume-independent effect of sodium. The results of this study may provide 
additional support for the use of dialysate sodium levels at the lower physiologic 
range and, where necessary, individualization of dialysate sodium levels.. 
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Sodium profiling improves hemodynamic tolerance in haemodialysis (HD) patients but may also influence 
sodium homeostasis. Changes in blood volume and plasma conductivity (PC) during HD can be modelled by 
feedback technology, but their effects on sodium homeostasis are not widely studied.  
 
Methods 
This randomized crossover study compared PC and ionic mass balance (IMB) as surrogate markers of 
sodium balance between standard HD [dialysate conductivity (DC) 14.0 mS/cm], sodium profiling (DC 15.0 - 
14.0 mS/cm), blood volume (BV)-controlled and PC-controlled feedback (target: post-HD PC: 14.0 mS/cm) in 
10 HD patients with frequent hypotension.  
 
Results 
440 treatments were studied. Pre-dialytic PC was significantly higher during sodium profile 
(14.4±0.2 mS/cm) compared to standard HD (14.2±0.3 mS/cm), and was not different between the other 
manoeuvres: PC-controlled (14.1±0.3 mS/cm), and BV-controlled feedback (14.2±0.2 mS/cm). Except for the 
first treatment, during which IMB was lower during the sodium profile, IMB did not differ significantly 
between the various manoeuvres and was strongly dependent upon ultrafiltration volume and the 
difference between pre-dialytic PC and DC. 
Symptomatic hypotensive episodes occurred least frequently during BV-controlled feedback (8%) compared 
to the other manoeuvres (standard HD, 16%; sodium profile, 14%; PC-controlled feedback, 17%), but 




Pre-dialytic PC increased during the sodium profile, and did not differ between BV- or PC-controlled 
feedback compared to standard HD. Thus, it appears that both BV- and PC-controlled feedback can be safely 
prescribed without substantial salt- and water-loading, at least in the short term. Analysis of IMB is useful to 
assess differences in sodium balance between single treatment sessions but appears of less value in a 
steady-state situation.  
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Introduction 
Sodium profiling with a high dialysate sodium concentration is an effective method for 
the prevention of intra-dialytic hypotension, but also has possible drawbacks such as 
increased thirst, inter-dialytic weight gain and hypertension1,2. Recently, it has become 
possible to model the decline in blood volume and changes in plasma conductivity 
(PC), as a surrogate of plasma sodium, by means of feedback technologies. With blood 
volume (BV)-controlled feedback technologies, a target for a maximal decline in BV is 
set, which is achieved by continuous adjustments of ultrafiltration rate and (when 
using the Hemocontrol© module) continuous adjustments of dialysate conductivity in 
response to measured changes in BV2. In the case of PC-controlled feedback, a target 
for end-dialytic PC is set, and achieved by frequent adjustments of dialysate 
conductivity during the dialysis sessions, in response to on-line measured changes in 
PC3–5. With both BV- and PC-controlled feedback, it is possible to achieve these targets 
with a high level of precision. Both modalities are theoretically appealing and were 
shown to be successful in clinical studies3–10, although clinical experience with 
conductivity-controlled feedback in particular is still limited5,10. Both modalities, 
however, also have potential caveats. From a theoretical point of view, the frequent 
adjustments of dialysate conductivity (DC) during BV-controlled feedback may lead to 
alterations in sodium removal compared to standard dialysis sessions. PC-controlled 
feedback treatments with generalized pre-set targets (such as a post-dialytic PC of 
14.0 mS/cm) may lead to reduced sodium removal in those patients with low pre-
dialytic plasma sodium levels. Little data on sodium balance during these different 
manoeuvres are available in the literature and are, in most cases, based on a limited 
number of measurements during the study period6–9. By means of assessment of ionic 
mass balance (IMB) and changes in pre-dialytic PC, it is possible to assess sodium 
balance during dialysis therapy in a non-invasive way during every dialysis 
treatment3,4,11. However, although IMB was able to detect differences in sodium 
transfer during a single treatment session11, its value in assessing chronic changes in 
sodium balance is not well established. The aim of the present study was to compare 
the effects of standard dialysis, a sodium with a mean dialysate sodium concentration, 
and PC- and BV-controlled feedback treatments on PC and IMB, as surrogate 
parameters for sodium balance. 
Subjects and methods 
Twelve patients with frequent symptomatic (see definition below) or asymptomatic 
hypotensive episodes (decline in systolic blood pressure below 100 mmHg) during 
dialysis (i.e. >2 during 3 weeks before the start of the study) were included in the 
study. One patient withdrew from the study because of mitral valve surgery, and one 
patient died from a cardiac arrest. Data from these patients were excluded from the 
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analysis. All patients had a residual glomerular filtration rate <2 ml/min. The origin of 
renal failure in the 10 patients who completed the study was diabetes mellitus (n=4), 
cholesterol emboli (n=1), chronic glomerulonephritis (n=3), hypertensive 
nephrosclerosis (n=1) and chronic interstitial nephritis (n=1). Other characteristics of 
the patients who completed the study are shown in Table 5.1. The study was 
approved by the Ethics committee of the Maxima Medical Centre. All patients gave 
written informed consent. 
 
Table 5.1 Patient characteristics. 
Age  71 ± 11 
Sex (M/F)  6 / 4 
Time on dialysis (months)  24.1 ± 17.7 
Duration of dialysis (hours)  3.9 ± 0.5 
Diabetes mellitus 6 (60%) 
Congestive heart failure (NYHA33) 4 (40%) 
Use of ACE inhibitors 4 (40%) 
Kt/V (single pool)  1.5 ± 0.2 
Serum albumin (g/l)  38.2 ± 3.8 
 
Design 
All patients were treated with standard HD treatment (DC 14.0 mS/cm), a linear 
decreasing sodium profile (DC 15.0 - 14.0 mS/cm), BV-controlled feedback (mean DC 
14.0 mS/cm) and PC-controlled feedback (target: post-dialytic PC 14.0 mS/cm). The 
treatment order was prescribed en blocs using a four-treatments, four-period 
randomized cross-over design. Patients were randomized into one of the following 
treatment blocks:  
I standard dialysis – sodium profile – BV-controlled feedback – PC-controlled 
feedback; 
II sodium profile – BV-controlled feedback – PC-controlled feedback – standard 
dialysis;  
III BV-controlled feedback – PC-controlled feedback – standard dialysis – sodium 
profile; or  
IV PC-controlled feedback – standard dialysis – sodium profile – BV-controlled 
feedback.  
During each block, patients received 11 consecutive treatments of this modality, 
followed by 1 week's treatment with standard dialysis in order to prevent possible 
carry-over effects, after which 11 treatments with the following modality were 
started, etc. Total duration of the study was 4 months.  
Dialysis schedule 
The dialysis schedule of the patients was 3 times weekly in all patients. Dialysis time is 
mentioned in Table 5.1. Polysulfone (F8HPS; Fresenius®) low flux dialysis membranes 
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were used. Composition of the dialysate was: potassium 2.0 mmol/l, calcium 
1.5 mmol/l, magnesium 0.5 mmol/l, bicarbonate 32 mmol/l, acetate 3.0 mmol/l and 
glucose 1 g/l. Temperature of the dialysate was 36°C. Patients were ultrafiltered until 
their clinically determined dry weight.  
Ionic mass balance 
IMB was estimated by Diascan® (Hospal-Gambro®, Lyon, France)4,11,12. In short, 
Diascan® measures IMB by constant measurement of the conductivity in the dialysis 
outlet and inlet according to the formula IMB = [(Qdout x Cdout – (Qdin x Cdin)]
 x 10 x 
time (min). Qdout and Qdin are dialysate flow at, respectively,
 outlet and inlet; Cdout and 
Cdin are dialysate conductivity
 at, respectively, outlet and inlet. A positive IMB reflects 
net sodium removal from the patient, a negative IMB means net sodium transfer from 
dialysate to the patient. 
Plasma conductivity 
PC was measured by Diascan® by measuring dialysance (D) in combination with 
measurements of Cdout and Cdin according
 to the formula:  
PC = [Cdout – (1 – D/Qdin) x Cdin]/(D/Qdin).
  
D is assessed every 30 min by measuring the increase in Cdout
 after a temporary 
increase in Cdin by 1 mS/cm according to the
 formula:  
D = (Qdin + Qf) x [1 – (Cdout1 – Cdout2)/(Cdin1 –
 Cdin2)].  
1 and 2 indicate, respectively, the measurements before and after the temporary 
increase in Cdin
4,11,12.  
Relative blood volume 
BV was measured continuously by continuous optical assessment of changes in 
hemoglobin during the dialysis session (Hemoscan®; Hospal-Gambro)13.  
Description of the feedback modules 
BV-controlled feedback (Hemocontrol®; Hospal-Gambro), described in detail 
elsewhere6, is achieved with a closed-loop automatic control system using three 
controlled variables and two control variables. The three controlled variables are total 
weight loss (TWL), BV change (determined by hematocrit measurements), and 
equivalent conductivity, a value derived from the DC which is defined as the 
conductivity value required to achieve the same sodium mass balance compared to 
standard HD6. The control variables consist of the set ultrafiltration rate (UFR) and the 
delivered DC. Discrepancies between ideal and achieved controlled variable values are 
processed by a multi-input/multi-output controller that in turn effectuates a response 
through the two actuators, the control variables UFR and DC. Changes in BV are 
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determined by Hemoscan® (see above). TWL is measured volumetrically. Before the 
start of the study, the patient underwent 10 regular treatments. During this period, 
the mean BV change at which hypotension occurred was recorded. The target BV:TWL 
ratio during BV-controlled feedback was 20% higher than this value.  
With PC-controlled feedback (Diacontrol®; Hospal-Gambro), PC is modelled 
automatically during dialysis by adjustment of DC using single-pool kinetic 
modelling4,5. PC is measured throughout the HD session by Diascan® as described 
above. The target post-dialytic PC was 14.0 mS/cm during all treatment sessions.  
Plasma sodium 
Plasma sodium was assessed by indirect ionometry (Vitros 950®), which assesses 
sodium activity in the plasma. Sodium activity is automatically converted to the molar 
ionized sodium concentration. Obtained values were corrected by converting the 
molar concentration to flame photometer values by a standard correction factor 
(0.93)10. The coefficient of variation for this method, as given by the manufacturer, is 
0.4%.  
Blood pressure measurements 
Blood pressure was assessed every 30 min with an oscillometric device (HDBPM 4; 
Hospal-Gambro). Also during each symptomatic event, blood pressure was measured.  
Definition of intra-dialytic hypotension 
Symptomatic hypotension was defined as a decline in systolic blood pressure to <100 
mmHg (in patients with pre-dialytic systolic blood pressure <110 mmHg), or a decline 
in systolic blood pressure larger than 30 mmHg together with typical symptoms, 
necessitating nursing interventions. Also all intra-dialytic morbid events (cramps, 
nausea, headache, abdominal pain, with or without hypotension) were recorded. Also 
all episodes with a decline in systolic pressure below 100 mmHg were recorded.  
Power analysis 
Primary outcome parameter was the difference in pre-dialytic PC between the various 
modalities. Assuming an SD of 0.2 mS/cm11, eight patients would be needed to show a 
mean difference of 0.2 mS/cm between two different treatment modalities with a 
level below 0.05 and a power of 0.80. Assuming an SD of 110 mmol for IMB11, nine 
patients had to be included in order to show a difference of 100 mmol with the same 
significance levels. In order to correct for multiple comparisons and drop-outs, 12 
patients were included.  
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Statistics 
Repeated measurements ANOVA was used to compare the different parameters 
between the various modalities. The mean value of the 11 treatments for each 
modality was entered into the analysis. To assess the determinants of IMB, 
multiregression analysis was used. Fisher's exact-test was used to assess differences in 
frequency of hypotension between the different modalities. P-values <0.05 were 
considered significant. The SPSS 12.0 package was used for statistical analysis.  
Results 
Data for IMB and PC were available for all sessions. In total, data of 440 sessions were 
analyzed.  
Plasma conductivity 
Mean pre- and post-dialytic PC were increased during the sodium profile compared to 
standard HD. Pre-dialytic PC did not differ between BV- and PC-controlled feedback 
compared to standard HD (Figure 5.1 and Table 5.2). Post-dialytic PC was significantly 



















Figure 5.1 Pre- and post-dialytic PC levels during the different modalities. Covered boxes indicate 25–
75% with median value; capped bars indicate the range of data. Dots indicate outliers. Both 
pre- and post-dialytic PC were significantly higher during the sodium profile compared to all 
other treatments (P<0.05). Post-dialytic PC was significantly lower during PC-controlled 
feedback compared to the other manoeuvres. 
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Table 5.2  
 Standard BV-feedback PC-feedback Sodium profile 
Pre-dialytic PC (mS/cm)a  14.22 ± 0.20  14.22 ± 0.17  14.14 ± 0.22  14.37 ± 0.14b 
Post-dialytic PC (mS/cm)a  14.11 ± 0.20c  14.11 ± 0.10c  14.03 ± 0.04b,c  14.42 ± 0.05b 
DC (mS/cm)a  14.06 ± 0.06  14.23 ± 0.04b  14.03 ± 0.12  14.42 ± 0.05b 
Ionic mass removal (mmol)  383 ± 112  432 ± 80  370 ± 140  414 ± 106 
IDWG  2.0 ± 1.0  2.2 ± 0.7  2.0 ± 0.9  2.1 ± 1.0 
Decline in relative BV (%)  -6.1 ± 2.4  -6.6 ± 2.3  -6.4 ± 3.1  -7.4 ± 2.1 
Pre-dialytic SBP (mmHg)  146 ± 26  140 ± 23  145 ± 19  144 ± 22 
Nadir dialytic SBP (mmHg)  111 ± 22  108 ± 19  111 ± 17  112 ± 18 
Post-dialytic weight (kg)  76.8 ± 14.2  76.1 ± 16.0  76.1 ± 14.8  76.5 ± 14.6 
PC, plasma conductivity; DC, dialysate conductivity; IDWG, inter-dialytic weight gain; SBP, systolic blood 
pressure; BV, blood volume. a P<0.05 (ANOVA); b P<0.001 compared to all other treatments; c P<0.001 
compared to pre-dialytic values. 
 
 
PC-controlled feedback was able to reach target post-dialytic PC levels within narrow 
limits (14.03±0.03 mS/cm). In those sessions in which pre-dialytic plasma conductivity 
levels were <14.0 mS/cm, as expected, PC increased significantly (+0.21±0.17; 
P<0.001) and declined during sessions when pre-dialytic PC was >14.0 mS/cm 
(-0.18±0.14; P<0.001). During PC-controlled feedback, the intra-individual coefficient 
of variation of pre-dialytic PC levels was 1.3%. Pre-dialytic PC varied between values 
above and below 14.0 mS/cm in six of the patients during the period with PC-
controlled feedback.  
Single measurements of pre-dialytic plasma sodium did not differ between the 
different modalities: 138±2 mmol/l during standard dialysis, 137±2 mmol/l during BV-
controlled feedback, 139±3 mmol/l during the sodium profile and 138±3 mmol/l 
during PC conductivity-controlled feedback.  
Ionic mass balance 
IMB during the first session was lowest during the sodium profile (315±157 mmol; 
P<0.05). Between the other manoeuvres, IMB during the first sessions did not differ: 
423±166 mmol during standard dialysis, 488±179 mmol during BV-controlled feedback 
and 409±109 mmol during PC-controlled feedback.   
During the remainder of the sessions, IMB did not differ significantly between the 
different treatment modalities (Table 5.2). 
However, during PC-controlled feedback, IMB was lower during the sessions when 
pre-dialytic PC was lower than 14.0 mS/cm (n=30) compared to sessions before which 
pre-dialytic PC was higher than 14.0 mS/cm (n=80). (248±98 vs 416±174 mmol/l; 
P<0.001) despite comparable ultrafiltration volume (2.0±0.7 vs 2.0±1.1 kg).  
Pooling all treatments, ionic mass removal was highly dependent upon both 
ultrafiltration volume (ß=0.72; P<0.001) and the difference between pre-dialytic 
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plasma conductivity and dialysate conductivity (ß=0.72; P<0.001) (Figure 5.2), but not 



















Figure 5.2 Relation between ionic mass balance and pre-dialytic and dialysate conductivity. (r2=–0.46; 
P<0.001). 
Inter-dialytic weight gain and blood pressure and blood volume 
Neither inter-dialytic weight gain nor pre-dialytic blood pressure differed significantly 
between the various treatment modalities (Table 5.2). Also post-dialytic blood 
pressure and the maximal decline in blood pressure were not significantly different 
between the various treatment modalities. The decline in BV was comparable 
between the various treatment modalities (Table 5.2).  
Intra-dialytic hypotension 
Symptomatic hypotensive episodes occurred least frequently during BV-controlled 
feedback (8%) compared to the other manoeuvres (standard HD, 16%; sodium profile, 
14%; PC-controlled feedback, 17%), but differences were not significant. The same 
held true for the total number of symptoms during dialysis (with or without 
hypotension): BV-controlled feedback, n=22; standard HD, n=31; sodium profile, n=29; 
PC-controlled feedback, n=32 (P=NS). The total number of sessions during which 
systolic BP declined to <100 mmHg did not differ significantly between the different 
manoeuvres: BV-controlled feedback, 26%; standard HD, 35%; sodium profile, 28%; 
PC-controlled feedback, 26% (P=NS).  
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The peak systolic blood pressure did not differ between the various sessions (Table 
5.2).  
Discussion 
In this randomized crossover study, we assessed the effect of a sodium profile and 
different feedback technologies on PC, IMB and haemodynamic tolerance. A 
significant increase in pre-dialytic PC was observed during the sodium profile, but not 
during BV-controlled feedback, whereas pre-dialytic PC was not different during PC-
controlled feedback compared to standard HD.  
IMB was lowest during the sodium profile, but only during the first session, and not 
during the remainder of the dialysis sessions with the sodium profile. IMB during the 
other modalities was comparable. The increase in pre- and post-dialytic PC, as 
surrogate markers of plasma sodium, is in agreement with various, but not all, earlier 
studies towards the effect of profiles with high mean sodium concentrations1,2. 
The effects of BV-controlled feedback on PC and IMB did not differ from standard 
dialysis. Data on the effects of BV-controlled feedback on sodium homeostasis are 
scarce, although earlier studies did not show a difference in plasma sodium levels 
compared to standard HD sessions. However, in these studies, serum sodium was only 
measured a few times during the study period, whereas in the present study, PC was 
assessed during all treatment sessions. 
With PC-controlled feedback, mean pre-dialytic PC was not different compared to 
standard dialysis. However, mean post-dialytic PC was significantly lower compared to 
standard HD. The target post-dialytic PC was 14.0 mS/cm in the present study. In 
agreement with earlier data from Locatelli et al.10, PC-controlled feedback was able to 
achieve this target within very narrow limits. However, caution should be applied with 
the use of PC-controlled feedback with generalized preset targets in patients with low 
pre-dialytic PC levels. An alternative approach given the intra-individual variation of 
predialytic PC or sodium levels may be the use of individualized targets for dialysate 
sodium or post-dialytic PC10,11,14.  
IMB was only significantly different between the first sessions of the different 
modalities, and not during the remaining sessions. This can be explained by the fact 
that, next to ultrafiltration volume, IMB is determined by the ratio between predialytic 
PC and dialysate conductivity11. Thus, as pre-dialytic PC increased during the sodium 
profile, the difference between PC and DC remained comparable to the other 
modalities, resulting in equal IMB. Therefore, the absence of differences in IMB 
between different dialysis modalities in a steady state does not imply that these do 
not differ in their effect on sodium balance. To estimate such an effect, measurement 
of plasma sodium or PC levels remains necessary. 
However, during PC conductivity-controlled feedback, IMB was lower when pre-
dialytic PC was <14.0 mS/cm compared with pre-dialytic PC levels >14.0 mS/cm. This is 
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due to the strong relation between pre-dialytic PC and dialysate conductivity. As in the 
majority of patients, pre-dialytic PC levels varied between values above and below 
14.0 mS/cm, IMB may be unpredictable when using generalized pre-set targets, as 
discussed previously.  
Despite differences in pre-dialytic PC, pre-dialytic blood pressure and inter-dialytic 
weight gain did not differ between the different treatment modalities. However, small 
effects on inter-dialytic blood pressure may have been missed in the present study, 
due to the absence of ambulatory blood pressure measurements.  
The effect of sodium profiling on inter-dialytic weight gain and inter-dialytic blood 
pressure control is not consistent between different studies. Whereas some studies 
found an increase in inter-dialytic weight gain and/or an increase in pre-dialytic 
systolic or inter-dialytic blood pressure, other studies did not1,2.  
A potential explanation for the absence of a difference in weight gain or blood 
pressure control between the various modalities may be strict adherence to fluid 
restriction by our patients. Regrettably, thirst sensation was not quantified in a 
structured way in the present study.  
The incidence of symptomatic intra-dialytic hypotension was lowest during BV-
controlled feedback, but differences between the various manoeuvres did not reach 
significance, due to underpowering of the study for this parameter. Earlier studies 
with larger number of patients have demonstrated the effect of BV-controlled 
feedback on intra-dialytic complications6,7,15–17.  
Except for the possible underpowering with respect to the secondary outcome 
parameter of intra-dialytic hypotension, some other drawbacks should also be 
mentioned. Firstly, PC and not plasma sodium was assessed in the present study, due 
to the fact that this parameter can be assessed on-line without need for blood 
sampling. Previous studies have shown a very close correlation between PC and 
plasma sodium levels11,18,19. However, PC is not equal to plasma sodium and, albeit to 
a much smaller degree, is also influenced by other electrolytes such as potassium. This 
might be reflected in the fact that post-dialytic PC was lower than pre-dialytic PC 
during all different modalities. From a theoretical point of view, differences in 
potassium and acid base balance are not to be expected between the different dialysis 
strategies studied in this paper. Indeed, frequent measurements of PC may be more 
sensitive in observing differences in sodium balance than single measurements of 
plasma sodium. In the present study, single measurements of plasma sodium did not 
differ between the various modalities.  
Lastly, the sodium profile used in the present study is only an example of many 
different sodium profiles described in the literature2. However, in the majority of 
effective sodium profiles high dialysate sodium concentrations are used. 
Summarizing, pre- and post-dialytic PC, as a surrogate marker of plasma sodium, 
increased during high-sodium profiling, but not during BV- or PC-controlled feedback 
treatments. Thus, it appears that both BV- and PC-controlled feedback can be safely 
prescribed without substantial salt- and water-loading, at least in the short term. 
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Except for the first treatment, IMB did not differ between the various manoeuvres, 
due to the equilibration between pre-dialytic PC and DC. Therefore, IMB appears of 
limited value to assess differences in sodium balance between different manoeuvres 
in steady state.  
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 Conductivitypulses, does it cause sodium burden?⏐89 
Recently, new techniques based on conductivity measurement enable the physician to 
evaluate the adequacy of hemodialysis dose (HDD) on all haemodialysis treatments by 
on-line monitoring of KT/V. Ionic dialysance (Diascan® Hospal®) is a parameter 
calculated from the dialysate conductivity at the dialyser inlet and outlet. Every half 
hour the inlet dialysate conductivity increases by 1 ms/cm during 5 minutes while the 
outlet dialysate conductivity-cell measures the effect of this increase. The calculated 
ion transfer across the membrane (largely sodium) is almost equivalent to urea 
transfer and therefore ionic dialysance reflects the urea clearance. This method has a 
good correlation with Kt/V measured by the mathematical urea equations in several 
studies1,2,3,4.  
However, some investigators suggest, that during the conductivity pulse of 5 minutes, 
significant amounts of sodium may be transferred into the patient5. In our centre we 
studied that effect. Diascan® also measures Ionic Mass Balance (IMB) and plasma 
conductivity (PC) which are likely to represent sodium balance and plasma sodium 
respectively (Plasma sodium in mmol/l ≈ plasma conductivity in ms/cm * 10). This is 
performed by constant measurements of the conductivity in the dialysate inlet and 
outlet, according to the formulas: 
PC = [Cdout – (1 – D/Qdin) x Cdin] / (D/ Qdin)  
Qdin and Qdout are dialysate flow at, respectively, inlet and outlet. Cdin and Cdout are 
dialysate conductivity at, respectively, inlet and outlet. D is Ionic Dialysance.  
IMB = [(Qdout x Cdout) - (Qdin x Cdin)]
 x 10 x time (min).  
A positive IMB means sodium removal from the patient. A negative IMB means 
sodium transport to the patient. 
In patients with zero inter-diaytic weight gain, IMB was measured in 200 isovolemic 
hemodialysis sessions by Diascan®, 137 sessions were performed with 4-8 
conductivity pulses. 63 sessions were performed with only 1 conductivity pulse. 
The results were that there was a highly significant correlation between pre-dialytic 
plasma conductivity and IMB (Spearman rank rs =0.902, P<0.005), in agreement with 
previous studies6. There was no correlation between IMB and the number of 












Figure 6.1 Correlation between IMB during isovolaemic haemodialysis and number of conductivity pulses.  
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In conclusion, Diascan® is a useful tool to assess dialysis dose without evidence of an 
increased sodium load related to the conductivity pulses during hemodialysis 
treatment.  
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In  830  hemodialysis  patients  from  the  NECOSAD  cohort  URR,  spKt/V  and  eKt/V  were  calculated  and 





A  spKt/V  of  ≥1.4  and URR  ≥  70%  corresponded with  eKt/V  ≥1.20  (as  reference method)  in  respectively 
98.0% and 90.6% of patients. spKt/V of ≥1.2 and URR ≥ 65% corresponded with eKt/V ≥1.05 in respectively 
95.5%  and  91.2%  of  patients.  Deviations  from  the  reference  method  were  significantly  related  to 
differences  in urea distribution  volume  (spKt/V),  treatment  time  (URR)  and ultrafiltration  volume  (URR). 





to  spKt/V.  Low  urea  distribution  volume,  short  treatment  time,  and  low  ultrafiltration  volumes  are 
predictive parameters for overestimation of dialysis dose when utilizing the alternative methods spKt/V and 




The  delivered  haemodialysis  treatment  dose  is  an  important  prognostic  factor  in 








is  used  to  assess  dialysis  adequacy.  The  calculation  of  spKt/V  is  somewhat more 







Various  guidelines  groups  have  defined  targets  for  dialysis  dose  prescription3,4. 
K/DOQI  guidelines  recommend measurement  of  haemodialysis  dose  using  spKt/V, 
whereas EBPG guidelines prefer using eKt/V3,4.  In addition, some national  registries, 
such as the UK Renal Registry [6], advocate the use of URR to assess dialysis adequacy. 
However, despite  the  fact  that  the EBPG on dialysis adequacy have been published 
various years ago, a recent survey by the EDTA‐QUEST [5] initiative showed that URR 














replacement  therapy  for  the  first  time.  Additional  criteria  for  the  present  analysis 







Patients  were  followed  at  three  and  six months  after  start  of  dialysis  treatment, 
thereafter  at  6‐monthly  intervals.  Data  for  dialysis  adequacy were  collected  at  12 
months after the start of dialysis, because stability in haemodialysis treatment may be 
assumed  (and  the  contribution of  residual  renal  function may be  less prominent as 
compared to the 3 and 6 months data). Body weight was measured before and after 
each  haemodialysis  session.  Treatment  characteristics  collected  were  dialysis 
frequency,  ultrafiltration  volume  and  treatment  time.  Blood  samples  were  drawn 
before and after a monitoring dialysis session and again before the following dialysis 
session. Urine was  collected  during  the  entire  interdialytic  interval.  Follow‐up was 
until time of death, transplantation, transfer to a non‐participating hospital, recovery 
of  renal  function  or  end  of  study  (20  August  2007).  Follow‐up was  censored  to  a 
maximum of 5 years.   
Data collection 
Demographic  and  baseline  data  were  obtained  0  to  4  weeks  before  the  start  of 
chronic dialysis treatment. Comorbidities were scored in case of presence of a doctors 




eKt/V was computed using  the Daugirdas‐Schneditz  rate equation  (Appendix 1) and 
considered as golden standard, while spKtV and URR were determined from the pre‐ 
en postdialysis blood urea nitrogen (BUN) using the two‐BUN method (Appendix 2+3). 
Urea  distribution  volume  (V) was  calculated  using Watson’s  formula  (Appendix  4). 
rGFR  was  estimated  according  to  the  formula  in  Appendix  5.  Since  residual  renal 
function may contribute significantly to final weekly Kt/V, the estimation of renal plus 
dialytic  Kt/V  allows  better  judgment  of  total  adequacy.  Therefore  rKt/V+eKt/V(wk) 
and  rKt/V+spKt/V(wk)  were  also  assessed.  eKtV  and  spKt/V  including  rGFR  were 






Target  dialysis  adequacy was  compared  between  the  target  levels  of  the  different 
methods:  eKt/V  >1.20  (target  EBPG  2001),  spKt/V  >1.40  and  URR  >70%  (target 
K‐DOQI).  
Dialysis adequacy was also  categorized  in order  to enable  comparison between  the 
different adequacy formulas with different units. This was achieved by classifying into 
three  categories.  The middle  category  of  each  of  the  dialysis  adequacy  formulas, 
considered  as  sufficient  dialysis  dose  and  defined  as  the  reference  group,  was 






models and descriptive statistics. Crude and adjusted hazard  ratios  for  the different 






with  haemodialysis.  In  830  of  those,  data  for  dialysis  adequacy  assessment  at  12 
months  after  the  start of dialysis were  available,  and were  included  in  the present 
analysis. 
Baseline  characteristics  of  these  patients  are  listed  in  Table  7.1. At  twelve months 
after start of dialysis mean age was 64, 41% was female, 21% had diabetes and 74% of 
the  haemodialysis  patients  were  treated  three  times  per  week  or  more.  Mean 
haemodialysis  treatment  time  was  10.29±1.97  hours/week.  In  Table  7.2  the 


















































Using  eKt/V  ≥1.2,  spKt/V  ≥1.4  and  URR  ≥70%  as  target  aims  for  adequate 
haemodialysis dose,  the  three different parameters were analyzed.  In 161  (19%) of 
the patients spKt/V dialysis dose was at or above  the  target range, without residual 
renal  function  taking  into  account.  However,  three  of  these  patients  (2%)  did  not 







Figure 7.1   Correlation between  single pool Kt/V and equilibrated double pool Kt/V  (r=0.994) and urea 
reduction  rate  and  equilibrated  double  pool  Kt/V  (r=0.953).  Panel  A  shows  classified  and 
misclassified  cases between minimal dose of  single pool Kt/V and equilibrated double pool 
Kt/V,  panel  B  shows  classified  and  misclassified  cases  between  minimal  dose  of  urea 
reduction rate and equilibrated double pool Kt/V. 
Panel C shows classified and misclassified cases between target dose of single pool Kt/V and 




A                                                               B
C                                                               D
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Table  7.3  summarizes  differences  in  characteristics  of  patients  in  which  dialysis 
adequacy would be overestimated when alternative methods  for estimating dialysis 
adequacy were used  instead of the gold standard. Treatment time and ultrafiltration 
volume were  significantly different  at  the misclassification when minimum dose of 
URR  was  reached  instead  of  eKt/V  (8.8  vs  10.2  hrs/wk  respectively  571  vs  1993 
ml/treatment;  P<0.001).  The  misclassification  using  spKt/V  instead  of  eKt/V  as 
minimal  cut‐off  point  showed  significant  differences  in  treatment  time  (9.3  vs 
10.4 hrs/wk) and urea distribution volume (31.1 vs 34.8 l; P=0.003). The disagreement 
of  reaching  target  dose  by  the  alternative  parameters  compared  to  the  golden 
standard  showed  the  same  significant  characteristics.  Treatment  time  and 
ultrafiltration  volume  were  significantly  different  between  the  classified  and 
misclassified patients when URR was used tot judge sufficient dialysis dose instead of 
eKt/V  (8.2  vs  10.2  hrs/wk  for  treatment  time  and  330  vs  1916 ml/treatment  for 





confounding  factors.  For  each  unit  increase  in  dialysis  adequacy,  the  adjusted  HR 
(95%CI) was  0.98  (0.96,  0.99)  for URR, 0.51  (0.31,  0.84)  for  spKt/V  and  0.46  (0.30, 
0.80)  for  eKt/V. When  dividing  the  groups  into  three  categories  (below minimum, 
above target, and  levels between minimum and target), with the  latter as reference, 
the trends  in survival between the different parameters remained, but only reached 





































































































































































































































































































































































































































































































































































































































































































































































































































URRa  1.08 (0.82, 1.43)  1.00  0.73 (0.51, 1.04) 
spKt/Vb  1.29 (0.98, 1.69)  1.00  0.86 (0.61, 1.20) 
eKt/Vc   1.46 (1.09, 1.95) #  1.00  1.07 (0.75, 1.52) 
rKt/V+spKt/V, wk b  1.23 (0.92, 1.65)  1.00  0.84 (0.63, 1.12) 












spKt/V  (4%).  All  adequacy  parameters  were  significantly  related  to  mortality. 
However, after categorizing patients according to minimum and target values of the 
different  adequacy  parameters,  only  for  eKt/V  mortality  rates  were  higher  when 
minimum levels were not met.  
There has been ample discussion about the recommended parameter for dialysis dose 
in  various  guidelines3,4.  Whereas  the  EBPG  recommends  the  use  of  eKt/V  as  the 
parameter of dialysis dose, spKt/V  is advocated by K‐DOQI. The rationale for the use 
of eKt/V by EBPG  is based on  the  fact  that urea  rebound after dialysis  is  taken  into 
account by adding a  time‐dependent  factor  to  the equation12. Especially  in patients 
treated with  very  short  dialysis  sessions,  the  difference between  spKt/V  and  eKt/V 
increases, which might result in overestimating dialysis adequacy when dialysis dose is 
valued by spKt/V2.  In contrast,  the K‐DOQI group decided  to maintain spKt/V as  the 
recommended parameter of dialysis dose, as shortened dialysis treatment times are 
not  allowed  by  both  K‐DOQI  and  EBPG  guidelines,  and  because  eKt/V  is  a 
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mathematical  derivative  of  spKt/V, which  cannot  be  adjusted  directly  by  changing 
treatment parameters3. 
In our study,  in only 4% of patients with a spKt/V  ≥1.2, eKt/V was  lower  than 1.05. 
Moreover, we  see  in  this  “misclassified”  subgroup a mean eKt/V of 1.03  (<1.05 but 
>1.01),  which  is  very  close  to  minimum  level.  The  notion  that  ultrashort  dialysis 
neither was nor is current practice in the Netherlands13, explains our observation that 
the great majority of patients with  spKt/V values above 1.2 had eKt/V  levels above 
1.05, whereas  in  those  patients who were  “misclassified”  according  to  spKt/V,  the 
difference with the eKt/V target was very small.  
For  calculation  of URR  only  pre‐  and  post‐dialytic  urea measurements  are  needed. 
Therefore, it is a simple and time‐saving calculated index18,22. However, weight of the 
patient, ultrafiltration volume and  treatment  time  is not  taking  into account  in  this 
formula and therefore deviations with the gold standard parameter may be assumed. 
Especially at higher levels of URR, the discrepancy with Kt/V was found to increase in 
previous  studies20,21.  Nevertheless,  in  the  present  study,  correlation  was  highly 
significant, but  relationship became  exponential  for  eKt/V  >1.3. Nine % of patients 
with  a URR  above minimum  (65%) had  eKt/V  below  1.05  (<1.05  but  ≥0.93). Mean 
eKt/V in these patients was 0.99. 
Differences in dialysis parameters which were related to misclassification when URR is 
used  instead  of  eKt/V  to  express  target  or  minimum  achieved  dose  were  sex, 
treatment  time  and  ultrafiltration  volume.  For  the  spKt/V  formula,  treatment  time 
(<10 hours a week) and urea distribution volume were  lower  in  those patients who 
were  above  the  minimal  dose  according  to  spKt/V,  but  below  the  minimal  dose 
according  to  eKt/V.  At  low  urea  distribution  volumes  and  short  treatment  time  a 
larger rebound effect will be expected, which might explain the discrepancy between 
URR and spKt/V with eKt/V. The relation between misclassification according to URR 
and  ultrafiltration  volume  can  be  explained  by  the  notion  that  convective  urea 

















Concluding,  the  results  of  our  study  show  that  treatment minimums  according  to 
eKt/V are overestimated by cut‐off values of spKt/V and URR  in respectively 4% and 
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agreement  between  equilibrated  Kt/V  assessed  by  urea  kinetic modelling  (eKt/V)  and  KIDt/V  taking
  into 
account  different  estimates  of  V,  and  to  assess  the monthly  variation  in  V.  Secondly,  the mechanisms 






















flow  were  the  main  determinant  of  variations  in  KIDt/V  (p<0.05).








method.  VIOD  and  VUKM,  should  be  assessed
  at  least monthly.  KIDt/V  varies widely  between  consecutive 




An adequate delivery of haemodialysis  treatment dose  is an  important  factor  in  the 
morbidity and mortality of patients treated with haemodialysis1. Regular evaluation of 
delivered  treatment  dose,  commonly  performed  by  measurement  of  Kt/V,  is 
necessary to intervene when the delivered treatment is inadequate. 
To assess Kt/V, the second generation Daugirdas formula is advocated by both K‐DOQI 
and  EDTA  guidelines2,3. Both  guidelines  recommend measurement of haemodialysis 





Techniques  based  on measurement  of  ionic  dialysance  facilitate  the  evaluation  of 
dialysis dose by online monitoring of the Kt/V (KIDt/V)
6–8]. Assessment of dialysis dose 
based  on  ionic  dialysance  was  shown  to  correlate  well  with  Kt/V  assessed  by 
traditional urea kinetic modelling8,9. However, despite highly significant correlations, 
several  studies  showed  either  lower or higher  values of KIDt/V  compared with Kt/V 
assessed by urea kinetic modelling. One reason for these differences is the fact that in 
some  studies, KIDt/V, which  is a  single‐pool
 model, was  compared with equilibrated 
Kt/V  (eKt/V)5,8. However,  another  factor which  is  likely  to  play  a major  role  in  the 












  which  correlated  very  well  with  V  obtained  by  direct  dialysis 
quantification and bio‐impedance measurements12,13. However, a comparison of VIOD 
with other estimates of V  regarding  the agreement between Kt/V, assessed by urea 
kinetic  modelling  and  KIDt/V  was  only  assessed  in  one  study  in  10  patients
13. 
Moreover,  the  frequency  by which  VIOD  or  VUKM would  have  to  be  assessed
  is  not 
known. 
Two  previous  studies  showed  substantial  inter‐treatment  variations  in  KIDt/V
5,14. 
Although  the mechanisms  behind  these  variations  remain  partly  understood,  inter‐
treatment  differences  in  dialysis  time  and  blood  flow  rate  appear  to  be  major 




due  to  the  conductivity  measurements  might  be  partly  responsible  for  this 
112⏐Chapter 8 
phenomenon,  also  a  reduction  in  clearance  per  se,  e.g.  due  to  fouling  of  the 
membrane, might lead to a reduction in  ionic dialysance. 
The primary aim of  the present study was,  firstly,  to assess  the agreement between 
KIDt/V with eKt/V taking into account
 different estimates of V. 









13  patients,  residual  renal  function was  present. Mean  GFR  in  these  patients was 














The  agreement  between  eKt/V  and  KIDt/V  was  assessed  after  the
  longest  dialysis 
interval. The inter‐treatment variation in KIDt/V (using VWatson) was assessed during six 
consecutive  treatments, as was  the  intra‐treatment variation  in  ionic dialysance. All 
treatments  were  monitored  for  changes  in  blood  flow,  relative  blood  volume, 




All but  three patients  (as mentioned  earlier) were  treated  three  times weekly with 
haemodialysis, using bicarbonate as buffer and a  sodium dialysate  concentration of 


















Determinants  of  inter‐treatment  changes  in  KIDt/Vwatson  were
  assessed  during  six 
consecutive treatments (n=396).  








taking  into  account  both  plasma  urea  samples  and  ionic  dialysance measurements 
(VIOD) (appendix)
12. Post‐dialysis blood samples for assessment of VIOD and VUKM were 
drawn  2 min  after  the  end  of  dialysis  using  the  slow  flow  technique11.  VUKM  was 
calculated using  the  calculator  available on  the HDCN page  (http://www.hdcn.com/ 
calcf/dzer.htm).  This  calculator  is  based  on  the  two‐urea  sampling  approach  as 
described  in19.  The  single‐pool  volume  is  corrected by  the programme  to  a double‐









The  agreement  between  data  was  analyzed  using  pearson's  r  and  Bland–Altman 
analysis21. Differences  between  eKt/V  and  KIDt/V  using  the  different  estimates  of V 
were  assessed  by  the  student  t‐test.  The  standard  deviation  in  KIDt/V  and
  ionic 
dialysance during the six different treatments were related to the standard deviation 
of  various  potential  determinants.  Multivariate  analysis  was  used  to  assess 
determinants of  inter‐dialytic variation  in KIDt/V and  intra‐treatment changes  in  ionic 
dialysance. P values <0.05 were considered significant. The variations in VIOD and VUKM 
were  also  assessed using  the  coefficient of  variation  and  the  intra‐class  correlation 





In  five patients with  inter‐dialytic weight  gain  <0.1  kg,  the  formula  for VIOD  yielded 
unreliable  results  (NB:  in patients with  inter‐dialytic weight  gain  >0.3  kg,  adequate 
values  for  VIOD  could  be  calculated.  No  patient  had  inter‐dialytic  weight  gains 
between 0.1 and 0.3 kg). Therefore, data of 61 patients were analyzed.  
The eKt/V was 1.19±0.21. KIDt/V was 1.12±0.21
 when  corrected  for VWatson  (p<0.001 







P<0.001),  both  when  using  VWatson
  and  VChertow  as  an  estimate  of  V,  although  a 
significant difference between both methods was observed  [0.08±0.13; P<0.05] and 
[0.20±0.13] with wide limits of agreement (Figure 8.1). Both when using VUKM and VIOD 













































































Intra‐class  correlation  coefficient  of  VIOD  was  0.87  when  VIOD
  measurements  were 



























































  β  05% CI  P 
Venous pressure  0.24  [0.00‐0.002]  0.06 
Ultrafiltration volume  ‐0.19  [‐0.038 to 0.014]  ns 
Blood flow  0.30  [0.00‐0.002]  0.016 
Dialysis time  0.13  [0.011 to 0.043]  ns 





  β  05% CI  P 
Venous pressure  ‐0.17  [‐0.28 to 0.05]  ns 
Ultrafiltration volume  0.09  [‐4.08 to 8.1]  ns 
Blood flow  0.15  [‐0.06 to 0.23]  ns 
Dialysis time  0.14  [‐1.3 to 5.7]  ns 





and  Kt/V  assessed  by  urea  kinetic  modelling,  but  showed  significant  differences 














results  of McIntyre  et  al. who  also  showed  comparable  values  between  eKt/V  and 
KIDt/V, but in contrast to the data of Filippo
 et al. who showed higher values for KIDt/V 
compared  with  eKt/V,  and  to  the  study  of  Wuepper  et  al.  where  KIDt/V  was 
comparable with  single‐pool  Kt/V5,12,13.  It  has  been  postulated  that  ionic  dialysance 
may underestimate effective urea clearance due to the effects of systemic salt loading 
during  the  ionic  dialysance  measurements,  resulting  in  a  reduced  conductivity 
diffusion  gradient  across  the  dialyser,  especially  when  urea  clearance  is  >150 
ml/min15. This might explain the fact that KIDt/V, both in our study and in the study of 
McIntyre, was  lower  than expected  for a single‐pool model5. However,  in chapter 6, 
we  found  no  evidence  for  systemic  sodium  loading  during  ionic  dialysance 
measurements when  assessed  during  an  entire  dialysis  session.  However,  possible 
effects on short‐term variations can not be refuted. Differences between the results 
obtained by Filippo et al. on one hand, and McIntyre and our study on the other hand, 
could  theoretically  be  explained  by  lower  levels  of  urea  clearance  in  the  former 
study5,12. However, this is unlikely in view of the fact that ionic dialysance in patients 
studied  by  Filippo  was  comparable  with  our  patients12.  In  contrast  to most  other 
studies, Wuepper  et  al. used  a model based on  a  two‐step  change  in  conductivity, 
which has different effects on systemic changes in sodium13,15.  
However,  even  with  a  two‐step  change  in  conductivity,  ionic  dialysance  may 
underestimate  urea  removal23,  which  may  be  related  to  the  effects  of 
cardiopulmonary recirculation24.  
VIOD,  calculated  according  to  single‐pool  kinetics,  yielded
  comparable  data  to  VUKM, 
calculated  according  to  double‐pool  kinetics.  This  is  in  agreement with  the  data  of 












If  V  is  to  be  assessed  by  VIOD  or  VUKM,  the  question  arises
  how  often  V  should  be 
measured.  Kloppenburg  et  al.  showed  relatively  large  intra‐patient  variability  in  V 
assessed by urea kinetic modelling4. From the data in the present study, the variability 
in  VIOD  or  VUKM  during  a  one‐month  period  would  appear  acceptable
  for  clinical 
purposes, but not when measurements of V are performed with longer time intervals. 
In  agreement  with  earlier  data  of  Lambie  et  al.14,  a  significant  inter‐treatment 
variation  in KIDt/V was observed.  In our  study,
  this variation appeared  to be mainly 
related  to  variations  in  blood  flow  rate.  Although  blood  flow  rate  is  routinely 
prescribed  as  300 ml/min  in  our  centre,  sometimes  the  blood  flow  rate  had  to  be 
decreased  in  response  to  changes  in  venous  or  arterial  pressure,  among  other 
reasons,  due  to  needle  malpositions.  The  variations  in  blood  flow  rate  between 
treatments are in agreement with the study of Lambie et al.14. In our study, changes in 
treatment  time  played  less  of  a  role  compared with  the  findings  of  Stewart  et  al. 
because treatment time was basically kept unchanged.  
In  the  present  study,  a  decline  in  ionic  dialysance  during  the  dialysis  session was 
observed, which also was described by Gotch et al.15. The change  in  ionic dialysance 
was  related  to  the  change  in  relative  blood  volume.  The  mechanism  behind  this 
phenomenon  remains  to  be  determined.  However,  it  may  be  hypothesized  that 
increased  clotting  of  proteins  to  the  dialyser membrane might  be  involved  in  less 
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   male is equal to 1 for males and 0 for females and 
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the  regulation  of  sodium  balance  during  dialysis.  These  aspects were  studied  both 
during routinely described hemodialysis as well as during different modifications, such 
as feedback technologies and sodium profiles.  





















* in this thesis, for sake of simplicity and in agreement with terminology in the literature, the term 
plasma conductivity is used, whereas the Diascan® device actually calculates conductivity in 
plasma water 
130⏐Chapter 9 
As described  in detail  in  Introduction of  the  thesis,  conductivity of a  solution  is  the 












Plasma sodium =  (Plasma conductivity x 10.4)  ‐ 9.57  1. Based on  results of different 
studies,  plasma  conductivity  appears  to  be  adequately  validated  as  surrogate 






in  full detail  in  chapters 3 and 4, with  a dialysate  conductivity prescription of 14.0 
mS/cm, dialysate sodium measurements by flame photometry and indirect ionometry 
were  comparable  (140.4±1.5  and  139.9±0.7 mmol/l),  but  lower when  assessed  by 
direct ionometry (135.4±1.1 mmol/l). As described in Introduction, this is likely due to 







on  changes  in  plasma  sodium  during  dialysis  and  ultrafiltration  volume,  Lambie 
observed a significant correlation between sodium balance assessed by  this method 




validated  against  sodium  balance  by  dialysate  collections  (in  which  sodium  was 
measured by flame photometry) and compared with the counted ions by the dialysis 
machine (Diascan®). Also, in this study, a very strong relation was observed between 
sodium  balance  and  ionic mass  balance  [r2=0.95],  although  in  individual  patients, 
some discrepancies between both methods were observed. Whether these are due to 













was clearly shown  in chapter 3 and 4,  in which a very strong  relation between pre‐
dialytic plasma conductivity and diffusive ionic mass balance was observed. Both in a 




was  0.2‐0.3 mS/cm  lower  than dialysate  conductivity, or when plasma  sodium was 
2 mmol  lower  than  dialysate  sodium.  In  basic  agreement,  in  the  database  study 











during  dialysis.  In  the  study  of  Song,  diffusive  sodium  influx  appeared  to  occur  at 
dialysate  sodium  levels  from  137.8 mmol/l6,  whereas  Flanigan  observed  an  inter‐
dialytic  increase  in  plasma  sodium  in  a  significant  subset  of  patients when  treated 
132⏐Chapter 9 
with  a  dialysate  sodium  concentration  of  140  mmol/l7.  Whether  the  (minor) 
differences between  studies  can be  attributed  to differences  in dialyzer membrane 





also  likely dependent on dialysis‐related  factors  such as ultrafiltration. According  to 




with  frequently  applied  sodium  concentrations  of  the  dialysate  (140  mmol/l),  in 
patients with  low pre‐dialytic plasma  sodium  levels, diffusive  influx of  sodium  from 
the  dialysate  to  the  patient may  occur.  Indeed,  although  ionic mass  removal  from 
patient to dialysate was observed  in nearly all treatments,  in nearly 33% of patients 
studied in chapter 4, diffusive ionic mass transfer from dialysate to patient and a rise 
in  plasma  conductivity  was  observed.  From  data  in  the  literature,  in  general,  a 
dialysate sodium concentration of around 137‐138 mmol/l would appear to provide a 
reasonable balance between the prevention of inward diffusive sodium mass transfer 
and  untoward  effects  of  too  low  dialysate  sodium  levels  on  blood  volume 
preservation8,9. For instance, lowering of dialysate sodium from 141 to 138 mmol/l at 
a  facility  level  resulted  in a small  improvement  in BP control without an  increase  in 
hypotensive  episodes8.  In  an  audit of 2187 patients,  the prescription of  a dialysate 
sodium  concentration  of  140  mmol/l  or  higher  was  associated  with  higher  inter‐
dialytic weight  gains,  pulse  pressure,  and  even with  a  higher  percentage  of  intra‐
dialytic  hypotension  as  compared  to  patients  whom  were  prescribed  a  dialysate 
sodium concentration of 136 or 137 mmol/l9.  
Whether particularly patients with  low pre‐dialytic  sodium  levels  and patients with 
difficult  to‐treat  hypertension  would  benefit  from  further  lowering  of  dialysate 
sodium  (e.g.  to 136 mmol/l)  is an  interesting  subject  for  future  studies.  In a  recent 
trial,  based  on  tolerability  of  the  participating  patients,  a  reduction  of  dialysate 
conductivity  of  up  to  13.0 mS/cm was  achieved  in  some  patients, with  beneficial 










Based  on  the  results  of  chapter  3,  ionic mass  balance  is  well  able  to  distinguish 
between treatments which differ in dialysate sodium prescription. Ionic mass removal 
was  significantly  lower  in patients  treated with a  supraphysiologic dialysate  sodium 
concentration  of  144  mmol/l  [80  mmol]  as  compared  with  a  dialysate  sodium 
concentration of 140 mmol/l.  In the study described  in chapter 5,  in which different 
maneuvers  used  to  prevent  intra‐dialytic  hypotension  were  compared  (including 
sodium  profiling),  each  during  11  consecutive  treatments,  difference  in  ionic mass 




conductivity. During  treatment with  the  sodium profile, due  to  the  increase  in pre‐
dialytic  plasma  conductivity,  the  ratio  between  the  dialysate  conductivity  and  pre‐
dialytic plasma conductivity remained unchanged. These results are in agreement with 
those of Lambie et al, in which a gradual reduction in dialysate conductivity resulted in 






loading  on  plasma  sodium  levels.  In  agreement  with  data  from  Thein8  but  in 
disagreement with  data  from  others2,6,12,  changes  in  dialysate  sodium  prescription 
resulted in changes in plasma conductivity (and thus plasma sodium levels) but not in 
changes  in  inter‐dialytic weight  gain. Whether  the  lack of  a  change  in  inter‐dialytic 




with  increased  inter‐dialytic weight, hypertension,  as well  as  the  effects on plasma 
conductivity observed  in  chapter 5 do not  support  the use of  sodium profiles with 
supraphysiologic  sodium  concentrations  as  a  preventive measure  for  intra‐dialytic 
hypotension.  Interestingly,  although  the  number  of  included  patients was  small,  in 
chapter 5, blood volume controlled feedback appeared to be an effective maneuver in 
the  prevention  of  intra‐dialytic  hypotension  without  untoward  effects  on  sodium 
balance. Blood volume controlled feedback is a concept at which ultrafiltration rate is 




Also  no  difference  on  sodium  balance  was  observed  during  plasma  conductivity 
controlled  feedback  compared  to  standard  dialysis.  Plasma  conductivity  controlled 
feedback  is a  technology at which dialysate conductivity  is adapted based on online 
measured  plasma  conductivity  to  reach  a  pre‐set  end‐dialysis  plasma  conductivity 
goal.  In this study,  in agreement with the available  literature at that time, we aimed 
for a post‐dialytic plasma sodium concentration15,16,17 of 14.0 mS/cm was chosen as 
target  (likely  corresponding  to  a  plasma  sodium  concentration  of  ±138  mmol/l). 
However,  in  some  patients  with  low‐predialytic  plasma  sodium  concentrations 
diffusive  sodium  influx might have occurred. Thus, especially  in  those patients with 





sodium  removal  in  those  patients with  low  pre‐dialytic  PC  level,  but  actually  in  a 
reduction  in  ionic  mass  removal  in  those  patients  with  higher  pre‐dialytic  PC. 
Therefore, at  least from theoretical premises, especially those patients with  low pre‐
dialytic  plasma  sodium  levels  patients  might  benefit  from  individualized  sodium 
prescription.  Data  in  the  literature  regarding  individualized  dialysate  sodium 
concentrations  are  scarce.  In  the  study  of  de  Paula18,  individualization  of  dialysate 
sodium  by manually  setting  dialysate  sodium  to  equal  patient  pre‐dialysis  plasma 
water sodium concentration, with a correction factor for the Donnan effect, resulted 
in  an  improvement  in  hypertension  control  and  a  decrease  in  inter‐dialytic weight 
gain. At the same time the  incidence of  intra‐dialytic hypotension reduced according 
to  treatments  with  a  fixed  dialysate  sodium  concentration  of  138 mmol/l.  In  this 
study, especially those patients with difficult‐to‐treat hypertension benefited from the 
lowering of dialysate  sodium. Pre‐dialytic plasma  sodium  concentrations before  the 
intervention were already quite  low  (134.0±1.4 mmol/l), which was due  to  the  fact 
that patients who had equal or higher plasma sodium concentrations were excluded 
from the study. A similar approach was followed by Sayarlioglu19, in which pre‐dialytic 
blood  pressure  and  inter‐dialytic  weight  gain  decreased  if  dialysate  sodium  was 
individualized  in patients with pre‐dialytic plasma  sodium  concentrations below  the 
standard  dialysis  sodium  concentration.  Notably,  in  all  these  studies,  only  stable 
dialysis patients without frequent intra‐dialytic hypotensive episodes were included.  
Thus, although more research is needed, individualization of dialysate sodium to pre‐
dialytic  plasma  sodium  concentration  appears  a  promising  tool,  especially  in  those 
patients with  low pre‐dialytic plasma  sodium  levels, high  inter‐dialytic weight gains, 
and  suboptimal  hypertension  control.  However,  for  individualization  of  plasma 
sodium, also more information on variations in pre‐dialytic plasma sodium (or plasma 
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conductivity) would be  interesting, given  the  controversial data  in  the  literature on 
the presence of a fixed osmolar setpoint in dialysis patients.  
Variations in pre‐dialytic PC 
In  order  to  explore  the  concept  of  individual  variations  in  pre‐dialytic  plasma 
conductivity, in chapter 4 a retrospective analysis of all treatments in the facility (4070 
measurements  in  73  patients) was  performed  during  a  period  of  6 months,  using 
plasma  conductivity  as  a  surrogate  for  plasma  sodium.  In  this  study,  the  mean 










assessment  of  plasma  sodium  or  plasma  conductivity  would  appear  a  reasonable 








per  individual  dialysis  patient)  has  to  be  purified  of  urea  (and  other  small  solutes) 
during  the  time  of  dialysis.  In  the  assessment  of  dialysis  adequacy,  there  is  a 
discrepancy between  the most  influential guidelines on  this  topic,  i.e.  the European 
Best  Practice Guidelines  (EBPG)  and  Kidney Disease Outcomes Quality  Initiative  (K‐
DOQI),  regarding  the assessment of Kt/V. Whereas K‐DOQI  recommends  the use of 
spKt/V  measurements,  EBPG  endorses  the  use  of  eKt/V,  which  corrects  for  urea 







different  adequacy  parameters.  It  is  also  not  known  whether  the  achievement  of 
treatment targets between the different adequacy parameter has different prognostic 
power. In chapter 7, these questions were addressed in 830 patients of the NECOSAD 
database.  eKt/V  above  1.2,  a  spKt/V  above  1.4  and URR  above  70% were  used  as 
targets for dialysis adequacy, and respectively 1.0, 1.2 and 65% as minimum levels.  
 
Only  5%  of  patients  with  spKt/V  above  1.4  had  an  eKt/V  below  1.2.  In  these 
“misclassified”  patients,  the mean  eKt/V was  1.19,  so  very  close  to  the  treatment 
target.  The  percentage  “misclassified”  patients was  somewhat  higher when  a URR 
>70% was used as parameter for treatment targets. More or less the same percentage 
“misclassified” patients was observed when the minimum levels for dialysis adequacy 




Concluding,  from  the  results  in  chapter 7,  the use of  either  spKt/V or  eKt/V  is not 
likely  to  have  a  major  effect  on  the  prescription  of  dialysis  therapy,  under  the 
condition  that  appropriate  cut‐off  levels  are  used.  The  risk  of  “misclassification” 
appears to be somewhat enhanced with the use of urea reduction rate as a parameter 
for  dialysis  adequacy.  Whether  this  carries  the  risk  of  inferior  patient  outcomes 
cannot be deduced from this thesis .  
Assessment of dialysis adequacy by ionic dialysance  
For  Kt/V  measurements  by  urea  kinetic  modeling,  blood  sampling  is  needed.  As 
described  in  the  introduction of  the  thesis, Kt/V assessment by  ionic dialysance  is a 
non‐invasive method  which  allows  to  assess  dialysis  adequacy  on  a  treatment‐to‐
treatment basis without  the need  for blood  sampling. This  is of  special  importance 
given the variety in intra‐patient Kt/V between treatments observed in chapter 8 and 
confirming  the  results  of  others22.  Although  dialysance  (the  diffusive  transfer  of  a 




similar  characteristics  of  transfer  through  the  dialyser  and  the  osmotic  distribution 
volumes  in  the  blood.  As  can  be  seen  in  the  figure  below,  ionic  dialysance  (by 
Diascan®)  is measured by assessing changes  in dialysate conductivity at  the dialyser 
outlet after a change in inlet dialysate conductivity. The change in outlet conductivity 
can be used to calculate ionic dialysance, assuming that plasma conductivity does not 
change during  the measurement24. A  very  strong  relation between  ionic dialysance 
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and  urea  clearance  has  been  observed.  However,  there  appears  to  be  a  small 
underestimation of urea clearance by  ionic dialysance, which may affect the relation 









Agreement between  ionic dialysance and urea kinetic modeling  in  the 
assessment of Kt/V 
Although Kt/V by ionic dialysance is a single pool method, both in the study described 
in  chapter 8 and  in various  studies  in  the  literature, Kt/V by  ionic dialysance, when 
assessed  by  the  Diascan® method,  appears  to  be  generally  lower  as  compared  to 
spKt/V by urea kinetic modelling24.  
 
Besides  this  (small)  underestimation  of  urea  clearance  by  ionic  dialysance,  this  is 
amongst others due to the method used to estimate urea distribution volume (V), as 
will  be  discussed  in  the  following  paragraph.  The  result  has  to  be  added  in  the 
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calculation of Kt/V by ionic dialysance, in order that V gets a substantial influence on 
the  final  result.  As  the  Watson  formula,  which  is  the  most  frequently  used 
anthropometric formula, tends to overestimate urea distribution volume, this would 
result  in a  too  low estimate of Kt/V. However, Kt/V measured by Diascan®  (a single 
pool method)  showed  better  agreement with  eKt/V  as  compared  to  spKt/V,  even 
when  this  was  calculated  by  V  by  urea  kinetic  modeling  (chapter  8).  The  good 
agreement between eKt/V and Kt/V by Diascan®  is  in agreement with  the  study of 
McIntyre et al.26.  
 
Another  factor which may  be  responsible  for  the  lower  estimate  of  Kt/V  by  ionic 
dialysance  as  compared  to  urea  kinetic  modeling  could  be  the  effect  of 







effect  of  the  conductivity  pulses  on  plasma  conductivity.  For  calculation  of  ionic 
dialysance,  it  is  assumed  that  plasma  conductivity  remains  unaffected  by  the 
conductivity pulse  itself. The  stability of  the plasma  conductivity  levels during  ionic 
dialysance measurements has been questioned by Gotch, who hypothesized that the 
conductivity pulses may  result  in  sodium  loading and  thus  in an  increase  in plasma 
conductivity28. In chapter 6, the effect of conductivity pulses on ionic mass balance in 
patients  treated  with  isovolemic  dialysis  was  assessed.  No  difference  in  IMB  was 







methods,  i.e.  the OCM monitor by Fresenius and Diascan by Gambro  in  the Kt/V29. 
Both methods have slightly different ways to deliver conductivity pulses. The Diascan 
method delivers a  conductivity  step of 1 mS/cm during a  short  time period, with a 
correction  needed  for  the  fact  that  outlet  dialysate  conductivity  is  not  completely 





Differences  between  ionic  dialysance  and  formal  urea  kinetic  modeling  are  also 
dependent on the method used for the determination of urea distribution volume in 
the  denominator.  Next  to  the  effects  of  cardiopulmonary  recirculation  on  the 
assessment  of  ionic  dialysance  discussed  above,  another  reason  for  the 
underestimation  of  spKt/V  by  ionic  dialysance  is  the  fact  that  the most  commonly 
used anthropometric  formulas  (e.g. Watson) overestimate urea distribution  volume 
(V) as compared to urea kinetic modeling.  
The  lower  urea  distribution  volume  by  urea  kinetic  modeling  as  compared  to 
anthropometric  formula  can  be  explained  either  by  the  fact  that  anthropometric 
formula do not  adequately  reflect  total body water  in dialysis patients,  e.g. by  the 
reduction in skeletal muscle mass and a relative increase in visceral fat distribution in 
dialysis patients30. On the other hand, also a functional redistribution of the urea pool 




modeling  to  calculate  urea  distribution  volume  resulted  in  an  improved  relation 
between Kt/V assessed by ionic dialysance and by blood sampling methods. However, 
the calculation of urea distribution volume by kinetic models is relatively complex for 
busy clinical practice, even with  the use of  internet‐based calculations, and  there  is 
need  for  blood  sampling.  This  complexity  especially  appears  to  hold  true  if  urea 
distribution  volume  is  calculated  by  the  ionic  dialysance  formula.  Moreover,  this 




Therefore,  the question  remains whether other methods which are easy  to apply  in 




anthropometric  formula were  used, whereas  the  use  of  bioimpedance  resulted  in 
comparable Kt/V  results  as  compared  to  calculation of urea distribution  volume by 
kinetic modeling32. Also,  in a preliminary study performed  in our unit, V by  the new 
bioimpedance  method  BCM®  (Fresenius)  was  significantly  lower  as  compared  to 




Concluding,  ionic  dialysance  has  greatly  facilitated  the  assessment  of  Kt/V,  and 
appears  to  be  relatively  widely  used  in  European  centers  according  to  a  recent 
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survey33.  However,  still  discrepancies  between  ionic  dialysance  and  formal  urea 
kinetic modeling are observed, which depend among others on  the method used  to 
assess ionic dialysance, on the methods of blood sampling, and on the methods used 
for  determination  of  the  urea  distribution  volume.  In  general,  underestimation  of 
spKt/V  by  Diascan®  would  have  less  serious  consequences  as  compared  to 
overestimation.  
 
Due  to  the  still  existing  controversies  with  regard  to  ionic  dialysance,  it  appears 
prudent to assess Kt/V by  formal urea kinetic modeling once monthly  in accordance 
with  current  guidelines.  And moreover  to  use  ionic  dialysance  as  a  tool  to  detect 
disturbances  in  delivery  of  dialysis  dose,  e.g.  by  access  circulation  or  frequent 
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Dit  proefschrift  bestaat  uit  twee  delen:  het  eerste  deel  richt  zich  op  verschillende 
aspecten met betrekking tot natriumbalans tijdens de hemodialyse behandeling. Deze 
werd  onderzocht  tijdens  reguliere  hemodialysebehandelingen,  maar  ook  tijdens 
alternatieve  hemodialysebehandelingen,  zoals  hemodialyse  met  behulp  van  bio‐
feedback of natriumprofielen.  






In  dit  proefschrift, worden  de  benamingen  plasma  natrium/plasma  geleidbaarheid, 
dialysaat  natrium/dialysaat  geleidbaarheid  en  natriumbalans/ionische massa  balans 
naast elkaar gebruikt met een overeenkomende betekenis.  
Het belangrijkste voordeel van plasma geleidbaarheid en ionische massabalans is dat 
ze allebei non‐invasief gemeten  kunnen worden  (zonder bloedafname) en  zijn, met 
















Zoals  in  de  Introductie  uitgebreid  beschreven  is,  is  de  geleidbaarheid  van  een 
oplossing  gelijk  aan  het  vermogen  om  elektrische  stroom  te  geleiden.  Plasma 
geleidbaarheid  wordt  beoordeeld  aan  de  hand  van  een  eenvoudige  wiskundige 
formule,  welke  rekening  houdt  met  ionische  klaring  en  veranderingen  in  de 









Plasma natrium =  (Plasma geleidbaarheid x 10.4) – 9.57  1. Gebaseerd op  resultaten 
van  verschillende  studies  mag  aangenomen  worden  dat  plasma  geleidbaarheid 








worden  deze  niet  gedetailleerd  beschreven.  Bij  een  ingestelde  dialysaat 
geleidbaarheid van 14.0 mS/cm, waren dialysaat natrium bepalingen door middel van 
vlamfotometrie  en  indirecte  ionemetrie  vergelijkbaar  (140.4±1.5  en  139.9±0.7 
mmol/l), maar weken af indien ze bepaald werden met behulp van directe ionemetrie 
(135.4±1.1 mmol/l). Zoals in de Introductie al beschreven, komt dit waarschijnlijk door 
complexvorming  van natrium met  andere  ionen  in het dialysaat, wat niet  gemeten 
wordt  door  directe  ionemetrie.  Daarom,  zoals  la Milla  ook  al  concludeerde3,  is  de 
bepaling van natrium uit verzameld dialysaat afhankelijk van de gebruikte methode en 




Voor  de  ionische massa  balans  (IMB)  als  surrogaat  voor  natriumbalans  tijdens  de 
dialysebehandeling zijn er minder gegevens beschikbaar  in de  literatuur. Lambie zag 
een significante relatie  tussen deze  twee methoden door gebruik  te maken van een 
formule  die  gebaseerd  is  op  veranderingen  in  plasma  natrium  tijdens  de 
dialysebehandeling en ultrafiltratievolume2.  In hoofdstuk 4 werd de  ionische massa 
balans gevalideerd  ten opzichte van de natriumbalans door dialysaat  te verzamelen 
tijdens  de  dialysebehandeling,  waaruit  natrium  werd  bepaald  door  middel  van 
vlamfotometrie,  en  te  vergelijken  met  de  getelde  ionen  door  de  dialysemachine 
(Diascan®). Ook  in dit onderzoek werd  een  sterke  relatie  gevonden  tussen natrium 
balans en  ionische massa balans  [r2=0.95], hoewel er binnen de  individuele patiënt‐
metingen  wel  discrepanties  gezien  werden  tussen  de  beide  methoden.  Of  deze 
verschillen  met  name  verklaard  worden  door  de  inherente  variatie  van  de 
natriumbepalingen, of mede door veranderingen in andere ionen in het dialysaat kan 
niet worden afgeleid worden uit dit onderzoek. In hoofdstuk 5, bleken ionische massa 









Verwijdering  van  natrium  tijdens  dialyse wordt  vooral  veroorzaakt  door  convectie. 
Daarentegen  zou  ook  diffusie,  veroorzaakt  door  verschil  in  plasma  en  dialysaat 
natriumconcentratie,  een  belangrijke  rol  kunnen  spelen.  Dit  werd  beschreven  in 
hoofdstuk  3  en  4,  waarin  een  zeer  sterke  relatie  tussen  predialyse  plasma 
geleidbaarheid en diffusieve ionische massa balans werd gezien. Dit werd aangetoond 










bij  een  ingestelde  dialysaat  geleidbaarheid  van  14  mS/cm  (dialysaat  natrium  140 
mmol/l). De mogelijke verklaring van de discrepantie tussen deze studies zou kunnen 
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zijn  dat  door  ultrafiltratie,  eiwit  coating  van  de  kunstnier  optreedt, waardoor  het 
Donnan  effect  beïnvloed  wordt  en  daardoor  de  diffusieve  ionische massa  balans. 
Daarnaast zouden pH veranderingen tijdens de dialysebehandeling het Donnan effect 
ook kunnen beïnvloeden4,5. 
In  het  onderzoek,  beschreven  in  hoofdstuk  4,  bleek  dat  diffusieve  ionische massa 
balans  voor  gemiddeld  18.3±16.7%  deel  uit maakte  van  de  totale  ionische massa 
balans.  Maar,  uit  de  grote  range  [0.4  ‐  75.3%]  bleek  dat  binnen  de  individuele 
patiënten, diffusieve ionische massa balans soms een groot onderdeel is van de totale 
ionische massa balans. 
Verschillende  andere  studies  hebben  ook  het  effect  van  dialysaat  natrium  op 
natriumbalans tijdens dialyse bestudeerd. In het onderzoek van Song, trad diffusieve 
natriuminflux op bij  een dialysaat natrium  vanaf 137.8 mmol/l6,  terwijl  Flanigan bij 





Conclusie:  er  is  een  sterke  relatie  tussen  pre‐dialytisch  plasma  natrium,  dialysaat 
natrium en ionische massa balans. Volgens de beschreven resultaten van hoofdstuk 4, 
wordt er geen belangrijke diffusieve natriuminflux van dialysaat naar patiënt verwacht 






natrium.  Dit  is  van  belang,  omdat  het  pre‐dialytische  plasma  natrium  bij  een 
aanzienlijk deel van de patiënten lager ligt dan 140 mmol/l. Bij 33% van de patiënten 
uit  hoofdstuk  4,  werd  diffusieve  natriuminflux  en  verhoging  van  de  plasma 
conductiviteit gezien, alhoewel bij bijna alle patiënten totaal ionisch massaverlies van 
patiënt  naar  dialysaat  werd  gezien  door  convectieve  verwijdering.  Volgens  de 
literatuur  wordt  in  het  algemeen  aangenomen,  dat  bij  gebruik  van  dialysaat 
natriumconcentratie van ongeveer 137‐138 mmol/l een redelijke balans wordt bereikt 
tussen, aan de ene kant het voorkomen van natriuminflux tijdens de dialyse en aan de 
andere  kant  effecten  van  een  te  lage  natriumconcentratie  op  bloedvolume‐
preservatie8,9. Bijvoorbeeld,  leverde het verlagen van dialysaat natrium van 141 naar 
138 mmol/ op een dialyse afdeling een kleine verbetering in bloeddruk op, terwijl de 
hypotensieve  periodes  tijdens  de  dialysebehandeling  niet  toenamen8.  Tijdens  een 
audit  van 2187 patiënten, werd  gebruik  van dialysaat natriumconcentratie  van  140 
mmol/l  of  hoger  geassocieerd met meer  interdialytische  gewichtstoename,  hogere 
polsdruk,  en  zelfs  met  een  hogere  incidentie  van  intradialytische  hypotensieve 
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episodes  vergeleken met  patiënten waarbij  een  dialysaat  natrium  van  136  of  137 
mmol/l9 werd gebruikt. 
Of  vooral  patiënten met  een  laag  pre‐dialytisch  plasma  natrium  en  patiënten met 
moeilijk te behandelen hypertensie zouden kunnen profiteren van het verder verlagen 
van  het  dialysaat  natrium  (b.v.  tot  136 mmol/l)  is  een  interessant  onderwerp  voor 
toekomstig  onderzoek.  In  een  recente  studie  van  Lambie  et  al., werd  bij  sommige 
patiënten  een  verlaging  van  dialysaat  geleidbaarheid  tot  13.0 mS/cm  bereikt, met 
bijkomende  voordelen  zoals  bloeddrukverlaging  en  verlaging  van  interdialytische 




Alhoewel  een  dialysaat  natrium  van  137‐138  mmol/l  bij  de  meerderheid  van  de 
patiënten  adequaat  lijkt,  worden  hogere  dialysaat  natriumconcentraties  en/of 
natriumprofielen  regelmatig  op  dialyseafdelingen  gebruikt  om  intradialytische 
hypotensie  te  voorkomen.  De  verbetering  van  refill  van  bloedvolume  vanuit  het 
interstitium  tijdens  ultrafiltratie,  opgewekt  door  de  natriumgradiënt,  ligt  aan  dit 






met  een  (hypertone)  dialysaat  natriumconcentratie  van  144  mmol/l  [80  mmol] 
vergeleken met een dialysaat natriumconcentratie van 140 mmol/l. In het onderzoek 
beschreven  in  hoofdstuk  5,  waarbij  verschillende  technieken  werden  uitgevoerd 
(gedurende  11  opeenvolgende  behandelingen)  om  intradialytische  hypotensie  te 
voorkomen,  (inclusief  natriumprofiel)  werd  een  verschil  in  ionische  massa  balans 
alleen  gezien  tijdens  de  eerste  behandeling met  een  natriumprofiel,  terwijl  bij  de 
volgende behandeling de predialytische plasma conductiviteit duidelijk verhoogd was 
tijdens  de  beginsituatie.  Waarschijnlijk  is  de  afwezigheid  van  verschil  in  ionische 
massabalans  na  de  eerste  behandeling  het  gevolg  van  de  sterke  relatie  tussen  de 
ionische  massabalans  en  de  predialytische  plasma  conductiviteit.  Tijdens  de 
behandelingen met natriumprofiel, waarbij de pre‐dialytische plasma geleidbaarheid 
steeg,  bleef  de  ratio  tussen  de  predialytische  plasma  geleidbaarheid  en  dialysaat 











anderen2,6,12,  veroorzaakten  veranderingen  in  dialysaat  natriuminstellingen 
veranderingen  in plasma geleidbaarheid, maar niet  in meer vochtintake. Of  in onze 




Literatuur  toont  aan,  dat  natrium  profielen  de  oorzaak  kunnen  zijn  van  verhoogde 
interdialytische  gewichtstoename,  hypertensie  en  effecten  op  de  plasma 
geleidbaarheid  zoals  die  in  hoofdstuk  5  beschreven  zijn,  waardoor  gebruik  van 
hypertone  natriumprofielen  wordt  afgeraden  om  intra‐dialytische  symptomen  te 
voorkomen.  Interessant genoeg, ook al was het aantal geïncludeerde patiënten  laag, 
bleek  in hoofdstuk 5 bloedvolume‐gecontroleerde  feedback een effectieve  techniek 
om  intra‐dialytische  hypotensie  te  voorkomen,  zonder  nadelige  effecten  op  de 
zoutbalans. Bloedvolume‐gecontroleerde feedback is een technologie waarbij op basis 
van  metingen  van  bloedvolume‐refill  continu  met  ultrafiltratiesnelheid  wordt 
gevarieerd, om zo een te snelle bloedvolumedaling (met als gevolg evt. hypotensie) te 
voorkomen.  De  effectiviteit  van  deze  biofeedback  technologie  komt  overeen  met 
andere studies, ook van onze dialyse afdeling13,14.  
Ook werd er geen verschil van zoutbalans gevonden  tijdens het gebruik van plasma 
geleidbaarheid‐gecontroleerde  feedback  vergeleken  met  standaard  hemodialyse. 
Plasma geleidbaarheid‐gecontroleerde  feedback  is een  technologie, waarbij op basis 
van online gemeten plasma conductiviteit de dialysaat conductiviteit zodanig varieert, 
zodat een vooraf ingestelde einddialyse plasma conductiviteit wordt behaald. In deze 
studie  werd,  in  overeenstemming met  de  beschikbare  literatuur  op  dat moment, 







literatuur.  In het onderzoek, beschreven  in hoofdstuk 3,  resulteerde  individualisatie 




opzichte  van  een  dialysebehandeling met  de  standaardinstelling. Om  die  reden,  in 
ieder geval vanuit theoretisch oogpunt, wordt verwacht dat vooral patiënten met een 
laag  pre‐dialytisch  plasma  natrium  zouden  kunnen  profiteren  van  een 
geïndividualiseerd dialysaat natrium. In het onderzoek van de Paula18, werd dialysaat 
natrium geïndividualiseerd, door handmatig het dialysaat natrium aan te passen aan 
het  pre‐dialytisch  plasmawater  natrium met  een  correctiefactor  voor  het  Donnan 




behandelen  hypertensie  voordeel  van  het  verlagen  van  het  dialysaat  natrium.  Pre‐
dialytisch plasma natrium was voor de start van het onderzoek al vrij laag (134.0±1.4 
mmol/l),  wat  veroorzaakt  werd  doordat  patiënten  met  hogere  plasma  natriums 
geëxcludeerd  werden.  Vergelijkbaar  onderzoek  werd  gedaan  door  Sayarlioglu19, 
waarbij de predialytische bloeddruk en interdialytische gewichtstoename afnamen op 
het moment dat het dialysaat natrium geïndividualiseerd werd bij patiënten met pre‐
dialytische  plasma  natrium  waarden  die  lager  waren  dan  de  standaard  gebruikte 
dialysaat  natriumconcentratie.  In  deze  studies  werden  alleen  stabiele  patiënten 
geïncludeerd, zonder frequente hypotensieve episodes. 
Al met al, hoewel er meer onderzoek nodig  is,  lijkt het  individualiseren van dialysaat 
natriumconcentratie een veelbelovend instrument, vooral bij patiënten met lage pre‐
dialytische  plasma  natriumwaarden,  hoge  interdialytische  gewichtstoenames  en 
ongecontroleerde  hypertensie.  Daarentegen,  zou meer  informatie  over  variaties  in 




is  er  een  retrospectieve  analyse  uitgevoerd,  beschreven  in  hoofdstuk  4,  van  alle 
dialysebehandelingen op een dialyse afdeling gedurende 6 maanden, waarbij plasma 
geleidbaarheid werd  gebruikt  als  surrogaat  voor  plasma  natrium.  In  dit  onderzoek, 
was  de  gemiddelde  variatie‐coëfficiënt  van  pre‐dialytische  plasma  geleidbaarheid 
1.3%.  Opvallend was  het  gemiddelde  intra‐individuele  verschil  van  ±0.9 mS/cm  [~ 
plasma  natrium  9 mmol/l]  tussen  de  hoogste  en  de  laagste  plasma  geleidbaarheid 
tijdens de  follow up van  zes maanden. Opmerkelijk  is, dat  inter‐ en  intradialytische 
verschillen in pre‐dialytische plasma geleidbaarheid correleerden met variaties in pre‐
dialytische  bloeddruk,  wat  een  bijkomstig  bewijs  zou  kunnen  zijn  voor 






plasma  natrium  of  plasma  geleidbaarheid  regelmatig  bepaald moeten worden.  De 
online beschikbaarheid op de dialysemachine van plasma geleidbaarheid lijkt een zeer 
handig  instrument om  individualisatie van dialysaat natrium  te bereiken, zonder dat 






de dialysebehandeling. De uitkomst  van deze parameter  is  een  getal, wat  aangeeft 
hoe vaak de V (berekend ureumdistributievolume per individuele patiënt) geklaard is 
van  ureum  (en  andere  kleinmoleculair  stoffen)  tijdens  de  totale  tijd  van  de 
dialysebehandeling.  Binnen  de  meest  invloedrijke  richtlijnen  over  dit  onderwerp, 
bijvoorbeeld  de  European  Best  Practice  Guidelines  (EBPG)  and  Kidney  Disease 
Outcomes Quality  Initiative  (K‐DOQI)  is er echter enige discrepantie met betrekking 
tot  de methodiek  van  de  Kt/V  bepalingen.  Aan  de  ene  kant,  adviseert  K‐DOQI  het 
gebruik van single‐pool Kt/V (spKt/V) metingen, terwijl EBPG het gebruik van double‐
pool  of  equillibrated  Kt/V  (eKt/V)  onderschrijft,  omdat  deze  voor  ureum  rebound 
corrigeert20,21. Uiteindelijk is eKt/V alleen een wiskundige correctie op de formule van 
spKt/V waarvoor  geen  extra bloedmonster  nodig  is. Beide  richtlijnen  adviseren  het 
gebruik van de ureum reductie rate (URR) alleen als aanvulling bij het beoordelen van 
dialyse adequaatheid. 
Het  is  niet  bekend  tot welke  hoogte  er  discrepantie  zou  kunne  bestaan  tussen  de 
verschillende  formules  in  de  beoordeling  van  de  adequaatheid  van  de 
dialysebehandeling. In hoofdstuk 7 is deze vraag onderzocht bij 830 patiënten van de 
NECOSAD database. eKt/V boven 1.2,  spKt/V boven 1.4 en URR boven 70% werden 





het  adequaatheids  doel. Het  percentage  “gemisclassificeerde” patiënten was hoger 
als  URR  was  gebruikt  als  formule  voor  adequaatheid.  Min  of  meer  dezelfde 




een  hoger  risico  op  overlijden,  wat  het  klinisch  nut  van  deze  formules  bij 
dialysebehandelingen aantoont.  
 
Vanuit  de  resultaten  van  hoofdstuk  7  kan  geconcludeerd worden,  dat  gebruik  van 
eKt/V  of  spKt/V  niet  zoveel  uitmaakt  voor  het  beoordelen  van  de  dialyse 
adequaatheid,  onder  voorwaarde  dat  er  goede  afkappunten worden  aangehouden. 
Het risico van “misclassificatie” wordt wat groter bij gebruik van URR, maar of dit ook 
invloed heeft op andere patiëntuitkomsten kan niet uit dit onderzoek herleid worden. 
Beoordeling  van  dialyse  adequaatheid  door  middel  van  ionische 
dialysance  
Voor  Kt/V  bepalingen  zijn  bloedafnames  nodig.  Zoals  in  de  introductie  van  dit 
proefschrift beschreven  is,  is Kt/V bepaling door middel van  ionische dialysance een 
non‐invasieve methode  die  het mogelijk maakt  om  tijdens  elke  dialysebehandeling 
dialysaat  adequaatheid  te  beoordelen  zonder  bloed  af  te  nemen.  Dit  kan  erg 
belangrijk zijn gezien de variatie  in bereikte Kt/V tussen verschillende behandelingen 
bij dezelfde patiënt, welke niet opgemerkt wordt wanneer de Kt/V alleen maandelijks 
bepaald  wordt  met  behulp  van  bloedafnames.  Deze  variaties  in  Kt/V  werd 





Kort  samengevat,  kan  ionische  dialysance  gebruikt  worden  als  surrogaat  voor 
ureumklaring,  omdat  deze  én  dezelfde  eigenschappen  van  transport  door  een 
kunstnier  hebben  én  dezelfde  osmotische  distributievolumes  in  het bloed.  Zoals  te 
zien op de figuur op pagina 152, wordt  ionische dialysance (door Diascan®) gemeten 
door  veranderingen  bij  de  dialysaatuitgang  te  beoordelen  aan  de  hand  van 
veranderingen in de dialysaatingang tijdens de dialysebehandeling. De veranderingen 
van  deze  dialysaatuitgang  worden  meegenomen  om  de  ionische  dialysance  te 
berekenen,  ervan  uitgaand  dat  de  plasma  geleidbaarheid  tijdens  die  meting  niet 
verandert24. Een zeer sterke relatie tussen  ionische dialysance en ureumklaring werd 



















Overeenkomst  tussen  ionische  dialysance  en  ureumkinetiek  bij  het 
beoordelen van Kt/V 
Ook al is Kt/V met behulp van ionische dialysance een single pool methode, toch valt 









om  deze  V  te  berekenen,  maar  deze  formule  heeft  de  neiging  om  het  ureum 
distributie  volume  bij  dialysepatiënten  te  overschatten,  waardoor  de  uiteindelijke 
Kt/V te laag uitvalt. Echter, zelfs wanneer V wordt berekend met een exactere formule 
volgnes het ureumkinetiek model,  laat Kt/V gemeten door Diascan® (een single pool 
methode), meer overeenkomst  zien met eKt/V dan met  spKt/V  (hoofdstuk 8). Deze 





door  middel  van  ionische  dialysance  vergeleken  met  de  Kt/V  door  middel  van 
ureumkinetiek,  is  het  cardiopulmonale  recirculatie  effect.  Cardiopulmonale 
recirculatie bestaat uit het effect dat een gedeelte van het gezuiverde bloed dat via de 
arterioveneuze shunt terug gaat naar het lichaam, direct via het hart weer de arteriële 
aansluiting  van  de  arterioveneuze  shunt  bereikt,  zonder  eerst  weer  via  lichaams‐




Een  andere  reden,  die  de  onderschatting  van  Kt/V  door  middel  van  ionische 
dialysance zou kunnen verklaren, zou het effect van de geleidbaarheids‐pulsen op de 
plasma  geleidbaarheid  kunnen  zijn.  Bij  de  berekening  van  de  ionische  dialysance, 
wordt  ervan  uitgegaan  dat  de  plasma  geleidbaarheid  constant  blijft,  ondanks  de 
geleidbaarheids‐pulsen  tijdens  die  meting.  Het  constant  blijven  van  de  plasma 
geleidbaarheid  tijdens  de  ionische  dialysance  meting  is  in  twijfel  getrokken  door 
Gotch,  die  beweerde  dat  de  geleidbaarheids‐pulsen  voor  extra  natriumbelasting 
zorgden en vervolgens voor verhoging van de plasma geleidbaarheid28.  In hoofdstuk 
6,  is  het  effect  van  deze  geleidbaarheids‐pulsen  op  de  ionische  massabalans 
onderzocht.  Geen  verschil  werd  gezien  tussen  behandelingen  met  of  zonder 
Diascan®metingen  in  ionische massa balans. Op  zich  is dit geen definitief argument 





In  Nederland  zijn  verschillende  merken  dialysemachines  beschikbaar  met  allen 
vergelijkbare  technische  opties  om  Kt/V29  te  meten.  Interessant  is  wel,  dat 
bijvoorbeeld  de  OCM®‐monitor  (online  clearance  monitor)  van  Fresenius  en  de 
Diascan® van Gambro een andere manier toepassen om de geleidbaarheids‐pulsen te 
doseren. Diascan®  verhoogt de  geleidbaarheid  gedurende  korte  tijd  tijdens de puls 
met 1mS/cm, terwijl OCM® gebruikt maakt van een drie fase geleidbaarheids‐puls met 
een  langere  stabilisatietijd24.  Of  deze  methodologische  verschillen  resulteren  in 
verschillen tussen de beide methodes dient verder onderzocht te worden. 
Ureum distributie volume 
Verschillen  tussen  ionische  dialysance  en  de  standaard  ureumkinetiek  voor  het 
bepalen van de dialyse‐effectiviteit, zijn ook afhankelijk van de methode die gebruikt 
wordt om het ureum distributie volume (V) te bepalen. Hiervoor  is het effect van de 
cardio  pulmonale  recirculatie  op  de  berekening  van  de  ionische  dialysance  al 
besproken. Daarnaast is het effect van de meest gebruikte antropometrische formules 
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(b.v. Watson) om V  te berekenen  een  andere  reden  voor het  verschil, omdat deze 
formules het ureum distributie volume overschatten.  
Deze overschatting kan verklaard worden, omdat antropometrische formules uitgaan 
van  een  standaard  lichaamsverdeling,  terwijl  bij  dialysepatiënten  vaker  het 
spierweefsel  afneemt  en  het  vetweefsel  relatief  toeneemt30.  Anderzijds  zal  de 
redistributie  van  het  ureum  naar  centrale  lichaamscompartimenten  (door 
verminderde  perfusiedruk  in  de  perifere  compartimenten),  als  gevolg  van  de 
dialysebehandeling,  bijdragen  aan  een  overschatting  van  het  ureum  distributie 
volume bij gebruik van de ureumkinetische methode. 
In hoofdstuk 8 werd aangetoond, dat indien gebruik gemaakt wordt van de kinetische 
formule  om  het  ureum  distributie  volume  te  berekenen,  de  relatie  tussen  ionische 
dialysance en ureumkinetiek (door middel van bloedafnames) sterker werd. Dit komt 
overeen  met  de  resultaten  van  di  Filippo31.  Helaas  is  deze  vorm  van  berekenen 
ingewikkeld voor de dagelijkse praktijk en  zijn er ook weer bloedafnames nodig om 
deze te kunnen berekenen.  Indien gebruik gemaakt werd van de  ionische dialysance 
formule  om  het  ureum  distributie  volume  te  bepalen  was  er  tevens  een  goede 
correlatie,  maar  deze  formule  bleek  niet  betrouwbaar  bij  patiënten  met 




volume  te  berekenen,  die  makkelijk  uitvoerbaar  zijn  in  de  dagelijkse  praktijk. 
Bioimpedantie  meting,  waarbij  het  totale  lichaamswater  wordt  geschat,  door 
elektrische geleiding van een wisselstroom door het lichaam, is makkelijk uitvoerbaar 
en non‐invasief. Uit  recent onderzoek van Lindley et al. bleek  (vergelijkbaar met de 
resultaten  uit  hoofdstuk  8)  een  onderschatting  van  de  dialyse‐effectiviteit  indien 
antropometrische  formules  (b.v. Watson) werden  gebruikt,  terwijl  het  gebruik  van 
bioimpedantie  resulteerde  in  vergelijkbare  Kt/V  uitkomsten  als met  behulp  van  de 
kinetiek  formule  om  het  ureum  distributie  volume  te  berekenen32.  Uit  een 
vooronderzoek van onze dialyse afdeling bleek ook, dat het ureum distributie volume, 
indien  het  gemeten  werd  door  de  bioimpedantie  methode  BCM®  (Fresenius), 
significant lager was dan wanneer deze gemeten werd door de Watson formule (32.4 
liters  ±  7.2  versus  34.9  liters  ±  6.1).  Het  effect  van  het  gebruik  van  deze  nieuwe 
methode bij de vergelijking van Kt/V  tussen ureumkinetiek en  ionische dialysance  is 
een belangrijk onderwerp voor vervolgonderzoek. 
 
Geconcludeerd  kan worden, dat  ionische dialysance de bepaling  van Kt/V  een  stuk 
makkelijker  maakt,  en  lijkt  ook  steeds  meer  gebruikt  te  worden  in  Europese 
dialysecentra33.  Toch  zijn  er nog  steeds discrepanties  tussen  ionische dialysance  en 
ureumkinetiek, veroorzaakt door onder andere de methode van bepaling van ionische 
dialysance,  de methode  van  laboratoriumbepaling  en  de methode  om  het  ureum 





Met  in acht neming van bovenstaande bezwaren,  zou  ionische dialysance een goed 
middel  kunnen  zijn  om  de  dialyse  effectiviteit  te  bewaken.  Als  tijdens  elke 
dialysebehandeling de  ionische dialysance wordt gecontroleerd kan, door deze trend 
te bewaken, geanticipeerd worden op elke verandering  in dialyse adequaatheid, b.v. 
door  shuntrecirculatie,  regelmatige  onderbrekingen  van  de  behandeling,  verkeerd 
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Sinds  1999  werk  ik  met  veel  plezier  als  (deeltijd)  researchverpleegkundige  op  de 
dialyse afdeling. Een leuke en interessante tijd heb ik beleefd in de periode waarin we 










Met veel enthousiasme heb  ik de afgelopen  jaren gewerkt aan het onderzoek wat  in 
dit  proefschrift  beschreven  staat.  Veel  heb  ik  geleerd  in  die  tijd  waarin  ik  van 





schrijven  is  van  jou,  dit  zou  nooit  in me  zijn  opgekomen.  Dankjewel  voor  je  blind 
vertrouwen  in mij  en  voor  je  bedrevenheid  om mij  te  stimuleren  en  te  inspireren, 
zodat  ik  altijd  op  de  terugweg  van  Maastricht  naar  Veldhoven  overliep  van 
enthousiasme om  verder  te  gaan op de  ingeslagen weg.  Jij was de onvermoeibare, 
stuwende kracht achter dit hele traject. Jouw wijsheid, kritische blik, nooit aflatende 
enthousiasme en positieve inslag hebben ervoor gezorgd dat ik met veel plezier terug 




met  het  onderzoek  in  een  perifeer  ziekenhuis.  Beste Charles,     omdat  je  zelf
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 gepromoveerd  was  kon  je mij  goed  voorbereiden  op wat  mij  te  wachten stond. 










van het proefschrift. Also  thank you dr. Peter Kotanko  for your participation  in  the 
thesis committee, and for willing to review my manuscript. 
 












vreemde  behandelingen  met  zoutprofielen,  ultrafiltratieprofielen,  Hemocontrol, 
Diacontrol,  waarbij    jullie  altijd  met  veel  interesse  en  enthousiasme  hielpen  met 
bedenken,  plannen,  uitvoeren  en  uitleggen.  Jullie  zijn  altijd  een  super  werkgroep 













was  voor  mij  altijd  stimulerend  en  je  bereidheid  om  te  helpen  verwarmend. 





was  werd  onttrokken  van  de  patiëntenzorg  om  dit  promotietraject  te  mogen 
volbrengen, heb  ik te danken aan de organisatie van het Máxima Medisch Centrum. 
Geweldig dat ik deze mogelijkheid heb gekregen in een voor het ziekenhuis niet altijd 
gemakkelijke  periode.  Dankjewel  Frans  Dreessen,  jij  hebt  dit  mede  voor  elkaar 
gekregen.  Math  Vankan,  ook  door  jou  kon  ik  mijn  onderzoek  voortzetten,  en 
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dankjewel  Linda,  Mariette,  Irena  en  Mary  voor  het  altijd  proberen  rekening  te 
houden met me en mij zo regelmatig mogelijk uit te plannen van de patiëntenzorg. 
 
Saskia  Houterman,  als  manager  van  het  wetenschapsbureau  was  je  altijd 







De  klinische  laboratoriumafdeling  van  het  Máxima  Medisch  Centrum  wil  ik  heel 
hartelijk  bedanken  voor  de  continue  bereidwilligheid  om  mee  te  werken  aan 
wetenschappelijk  onderzoek.  Ik  kon  altijd met  vragen  bij  jullie  terecht. Met  name 









Dank  jullie  allen  voor  het  kijkje  dat  ik  mocht  nemen  in  jullie  professionele 
onderzoekssetting. Vooral Els Boeschoten, Friedo Dekker en Diana Grootendorst wil 
ik  heel  hartelijk  bedanken  voor  de mogelijkheid  om  in  een  academisch  ziekenhuis 













waren  in de  fase waarin  ik was met mijn onderzoek. Vooral meneer Kouwenhoven, 
meneer  Roes  en  meneer  Ferrero  toonden  altijd  oprechte  belangstelling.  Dat  jullie 
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ondanks  jullie  vaak  zorgelijke  gezondheidstoestand  toch  nog  energie  op  konden 
brengen om naar mijn voortgang te vragen heeft mij erg geraakt. 
 
Lieve René  en Mirjam, bedankt dat  jullie mij willen  steunen  als paranimfen. René, 
mijn steun en toeverlaat toen we op de afdelingen begonnen met ons onderzoek naar 
Hemocontrol. Mede  door  jouw  enthousiasme  en  inzet  heeft mijn  onderzoeksdrive 
zich  toen ontplooid. Mirjam,  jij hebt  altijd  al bewezen dat  je door  gewoon hard  te 
werken  zonder  te  klagen  alles  kunt bereiken.  Ik heb  altijd  veel bewondering gehad 















































atheneum  aan  het  Bisschoppelijk  College  te Weert.  In  datzelfde  jaar  begon  zij  de 
inservice opleiding voor A‐verpleegkundige van het (destijds nog) st Joseph Ziekenhuis 
in Eindhoven en rondde deze  in 1992 af. Na een  jaar als  invalkracht op verschillende 




de  Transfergroep  in  Rotterdam  volgde.  Daarnaast  was  zij  tot  2004  werkzaam  als 
kwaliteitsmedewerker en was zij bestuurslid van de L.V.D.T. Na een aantal jaren actief 
te zijn geweest als onderzoeksverpleegkundige voor diverse externe studies, startte zij 
in  2001  met  eigen  onderzoek  in  samenwerking  met  het  Maastrichts  Universitair 
Medisch  Centrum.  Gestart  werd  met  onderzoek  naar  de  meerwaarde  van 
bloedvolume  gestuurde ultrafiltratie met de  dialysemachine  (Hemocontrol). Daarna 
werd dit uitgebreid naar andere opties van deze machine. Een deel van dit onderzoek 
is beschreven in dit proefschrift.  
 

